



FICHE D'IDENTIFICATION DU CRCM

Centre de Recherche en Cancérologie de Marseille

Direction du Centre

Directeur :	Jean-Paul BORG	jean-paul.borg@inserm.fr
Directeurs adjoints :	Vincent GELI	vincent.geli@inserm.fr
	Juan IOVANNA	juan.iovanna@inserm.fr
Directrice Administrative et Financière :	Marie-France TINLAND	marie-france.tinland@inserm.fr

04 86 97 72 00

Lieux d'implantation

Centre de Recherche en Cancérologie de Marseille, CRCM
Inserm UMR1068, CNRS UMR7258, Aix Marseille Université U105, Institut Paoli Calmettes
27 Bd Leï Roure
CS 30059
13273 MARSEILLE CEDEX 09

Campus Luminy : Centre de Recherche en Cancérologie de Marseille, CRCM
Campus de Luminy, Case 915, 163 Avenue de Luminy
13288 MARSEILLE CEDEX 09

Campus Timone : Centre de Recherche en Cancérologie de Marseille, CRCM
Faculté de Pharmacie, Campus de la Timone
27 Boulevard Jean Moulin, 8ème étage aile C
13385 MARSEILLE CEDEX 5

Site Web : <https://www.crcm-marseille.fr>

Tutelles

Aix-Marseille Université	CNRS
Inserm	IPC

Disciplines d'appartenance

DS 5 – Biologie, médecine, santé

Ecoles Doctorales de rattachement

Sciences de la Vie et de la Santé (ED 62)
Sciences Chimiques (ED 250)

Composition du Centre

- | | |
|---------------------------------|----------------------|
| - Enseignants – Chercheurs : 14 | - BIATSS / ITA : 139 |
| - Chercheurs : 105 | - Doctorants : 94 |
| - PU-PH / PH / MCU-PH : 57 | - Masters : 54 |

Equipes de recherche / Thématiques

E1 : Interactions Leuco/Stromales dans l'Hématopoïèse normale et pathologique

RESPONSABLE : Michel AURRAND-LIONS

E2 : Mécanismes Moléculaires de la migration des Cellules Tumorales

RESPONSABLE : Ali BADACHE

E3 : Apprentissage Automatique pour l'Oncologie de Précision et la Conception de Médicaments

RESPONSABLE : Pedro BALLESTER

E4 : Anticorps Thérapeutiques et Immunociblage

RESPONSABLE : Patrick CHAMES

E5 : Polarité cellulaire, Signalisation et Cancer

RESPONSABLE : Jean-Paul BORG

E6 : Biologie structurale et Chimie-Biologie intégrée

RESPONSABLES : Yves COLLETTE / Xavier MORELLI

E7 : Signalisation, Hématopoïèse et Mécanismes de l'Oncogenèse

RESPONSABLES : Patrice DUBREUIL / Paulo DE SEPULVEDA

E8 : Facteurs épigénétiques dans l'Hématopoïèse normale et pathologique

RESPONSABLE : Estelle DUPREZ

E9 : Contrôle des endonucléases à spécificité de structure et Stabilité du Génome

RESPONSABLE : Pierre-Henri GAILLARD

E10 : Télomères et chromatine

RESPONSABLE : Vincent GELI

E11 : Cancer du Pancréas

RESPONSABLE : Juan IOVANNA

E12 : Dynamique du Génome et Recombinaison

RESPONSABLE : Bertrand LLORENTE

E13 : Recombinaison Homologue, NHEJ et Sauvegarde de l'Intégrité Génomique

RESPONSABLE : Mauro MODESTI

E14 : Immunologie et cancer

RESPONSABLES : Daniel OLIVE / Jacques NUNES

E15 : Dommage de l'ADN et Instabilité du Génôme

RESPONSABLE : Vincent PAGES

E16 : Régulation spatio-temporelle de la signalisation

RESPONSABLE : Pascale ZIMMERMANN

E17 : Oncologie Prédictive

RESPONSABLES : François BERTUCCI / Emilie MAMESSIER

E18 : Cellules Souches Epithéliales et Cancer

RESPONSABLES : Emmanuelle CHARAFE-JAUFFRET / Christophe GINESTIER



E ATIP/AVENIR : Lésions de l'ADN par pontage inter-brin et maladies du sang
RESPONSABLE : Christophe LACHAUD

Plateformes scientifiques

Cytométrie

RESPONSABLES : Daniel OLIVE / Manon RICHAUD

(Epi)génomique

RESPONSABLES : Max CHAFFANET / Nadine CARBUCCIA

Histo-Pathologie Expérimentale

RESPONSABLES : Michel AURRAND-LIONS / Emmanuelle CHARAFE-JAUFFRET

Immunomonitoring

RESPONSABLES : Daniel OLIVE / Bernadette BARBARAT

Nanobodies

RESPONSABLES : Daniel BATY / Patrick CHAMES

Centre de Ressources Biologiques en Oncologie, Thérapie Cellulaire

RESPONSABLE : Christian CHABANNON

Recherche Clinique

RESPONSABLES : Dominique GENRE / Lilian LABORDE

Bioinformatique Intégrative

RESPONSABLES : Ghislain BIDAUT / Samuel GRANJEAUD

DOSynth

RESPONSABLE : Sébastien COMBES

SMARTc

RESPONSABLES : Nicolas ANDRE / Joseph CICCOLINI

DISC (datacenter)

RESPONSABLE : Bernard CHETRIT

Culture Cellulaire

RESPONSABLE : Juan IOVANNA

MAP (Protéomique)

RESPONSABLES : Jean-Paul BORG / Stéphane AUDEBERT / Luc CAMOIN

Int3D

RESPONSABLE : Philippe ROCHE

MISC (Imagerie)

RESPONSABLES : Ali BADACHE / Daniel ISNARDON / Rania GHOSOUB

Animalerie/Transgénèse

RESPONSABLES : Jean-Christophe ORSONI / Sylvie MARCHETTO / Olivier CABAUD

TrGET, Essais Précliniques

RESPONSABLES : Yves COLLETTE / Rémy CASTELLANO



3D-Hub-O

RESPONSABLES : Géraldine GUASCH / Véronique CHEVRIER

HiTS/IPCdd – Plateforme de criblage à haut débit

RESPONSABLES : Xavier MORELLI / Carine DERVIAUX

Services Communs

Administration

RESPONSABLE : Marie-France TINLAND

Laverie/Magasin

RESPONSABLE : Marie-Noëlle SIMON

Informatique

RESPONSABLE : Bernard CHETRIT

Présentation du Centre (10 à 15 lignes)

Le Centre de Recherche en Cancérologie de Marseille (CRCM) est affilié à l'Inserm (UMR1068), au CNRS (UMR7258), à l'Université Aix-Marseille (UM105) et au Centre de Lutte Contre le Cancer de la région PACA, l'Institut Paoli-Calmettes (IPC). Il comprend près de 450 personnes dans 19 équipes et 19 plateformes/plateaux technologiques coordonnés sous forme d'un CoreTech. C'est un centre avec plus de 25 nationalités représentées, collaborant avec les plus grands instituts nationaux et internationaux et membre de multiples réseaux d'excellence de recherche sur le cancer. La recherche au CRCM aborde les aspects fondamentaux de la recherche en cancérologie, allant de l'initiation au développement du cancer jusqu'à sa dissémination sous forme plus agressive (métastatique) en identifiant les altérations moléculaires, les mécanismes d'instabilité du génome et de sa réparation et en étudiant leurs conséquences fonctionnelles dans des contextes in vitro et in vivo. La contribution du microenvironnement tumoral et du système immunitaire est un autre domaine de recherche important du CRCM. Cette recherche interdisciplinaire est effectuée aux niveaux moléculaire, cellulaire et physiopathologique, à l'aide de modèles cellulaires simples ou complexes (organoïdes) ou récapitulant chez l'animal les étapes du processus tumoral. Ces approches multi-échelles permettent d'identifier de nouvelles cibles thérapeutiques et visent à développer des approches innovantes ciblant les altérations de la cellule cancéreuse ou de son environnement dans le but de progresser vers de nouveaux traitements. La recherche translationnelle et clinique permet d'identifier de nouveaux biomarqueurs de pronostic et de diagnostic et de lancer des essais cliniques innovants étroitement liés aux activités de laboratoire, une stratégie qui est un autre atout majeur du CRCM et de l'IPC. Ce continuum de science fondamentale-translationnelle-clinique est la marque de fabrique du CRCM, en cohérence avec les missions fondatrices de l'IPC, - soins, éducation, recherche et innovation pour les patients - et se traduit par de nombreuses publications conjointes entre chercheurs et cliniciens. Avec l'aide de ses services administratifs et financiers, l'équipe de direction du CRCM apporte le soutien nécessaire à ces travaux de recherche et promeut une politique forte de transfert technologique et de valorisation socio-économique. Le CRCM est également fortement impliqué dans la formation par le biais de son implication dans les parcours de Masters et de Doctorat de l'Université Aix-Marseille et de l'Institut universitaire en Cancer et Immunologie, Imagerie et Intelligence Artificielle.

Axes de recherche

Oncologie / Immunologie

Masters et Doctorats (Formations auxquelles participe le Centre)

Ecole Doctorale des Sciences de la Vie et de la Santé (ED 62) et Sciences Chimiques (ED 250)

Master Bio-informatique,

Master Bio-informatique, Biologie Structurale et Biochimie,

Master Biologie computationnelle,

Master Biologie intégrative et physiologie,

Master Biologie Moléculaire et Cellulaire,



Master Biologie Santé,
Master Biologie structurale, génomique,
Master Biotechnologies,
Master Cancer Biology,
Master Immunologie,
Master Ingénierie de la santé,
Master Métiers de l'enseignement, de l'éducation et de la formation,
Master Microbiologie.

Evènements 2019 – 2020 (Congrès, Collaborations nationales et internationales, Prix)

2019

- Table ronde : Hétérogénéité tumorale
- Journée d'accueil Professeurs du secondaire
- Participation au dispositif : Apprentis chercheurs (association *Arbre des Connaissances*) : accueil 7 après-midis sur 6 mois d'un duo lycéen-collégien
- Conférences Grand Public : Université du Temps Disponible
 - Vincent GELI : « Comment une cellule devient cancéreuse et les stratégies pour la combattre »
 - Jacques NUNES : « Nutrition, immunité et cancers »
 - Christophe DE LA ROCHE ST ANDRE : « L'épigénétique : existe-t-il une hérédité au-delà des gènes ? »

2020

- 40ème congrès de la SFH : Paulo DE SEPULVEDA
- 🔗 Sunrise : Emmanuelle CHARAFE et Christophe GINESTIER
- Institut Cancer&Immunologie : Conférence annuelle – Jean-Paul BORG
- 🔗 ImmunoSEM meeting en collaboration avec Bristol Myers Squibb : Jacques NUNES

Prix 2019

- **Anaïs AULAS** : Prix Kerner, coup de cœur des donateurs (Fond. ARC)
- **Clémence DEMERLE** : Prix de la Société Française de Pharmacologie
- **Esmâ KARKENI** : Prix du meilleur poster du public, Cancéropôle PACA
- **Victoire GOUIRAND** : Prix de la meilleure Thèse 2018 (remis en 2019) d'Aix-Marseille Université
- **Jérémy NIGRI** : Prix du meilleur poster en recherche translationnelle, Cancéropôle PACA
- **Vincent GELI** : Prix Jules Martin, Académie des Sciences
- **Julien GRENIER** : Prix du jury Hélène Starck (Fond. ARC)

Prix 2020

- **Eddy PASQUIER** : Médaille de bronze CNRS
- **François BERTUCCI** : Grand Prix de la Recherche Ruban Rose



LES PUBLICATIONS DU CRCM – 2019

1. Ackermann,C.J., Reck, M., Paz-Ares, L., Barlesi, F., and Califano, R. First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light. *Lung Cancer*. 2019;134:245-253.
I.F.: 4.702
2. Andre,N., Corradini, N., and Shaked, Y. Metronomic Maintenance Therapy for Rhabdomyosarcoma. *Trends Cancer*. 2019;5:756-759.
I.F.: 11.093
3. Arcani,R., Venton, G., Colle, J., Suchon, P., Ivanov, V., Mercier, C., Farnault, L., Roche, P., Lafage, M., Brunet, C., Azouza, W., Pourroy, B., Fanciullino, R., and Costello, R. Efficacy and safety of autologous stem cell transplantation after induction therapy with Lenalidomide, Bortezomib and Dexamethasone. *Eur J Haematol*. 2019;103:385-392.
I.F.: 2.220
4. Arfaoui,A., Rioualen, C., Azzoni, V., Pinna, G., Finetti, P., Wicinski, J., Josselin, E., Macario, M., Castellano, R., Leonard-Stumpf, C., Bal, A., Gros, A., Lossy, S., Kharrat, M., Collette, Y., Bertucci, F., Birnbaum, D., Douik, H., Bidaut, G., Charafe-Jauffret, E., and Ginestier, C. A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells. *EMBO Mol Med*. 2019;11:e9930
I.F.: 8.821
5. Au,C., Gonzalez, C., Leung, Y. C., Mansour, F., Trinh, J., Wang, Z., Hu, X. G., Griffith, R., Pasquier, E., and Hunter, L. Tuning the properties of a cyclic RGD-containing tetrapeptide through backbone fluorination. *Org Biomol Chem*. 2019;17:664-674.
I.F.: 3.490
6. Auliac,J.B., Perol, M., Planchard, D., Monnet, I., Wislez, M., Doubre, H., Guisier, F., Pichon, E., Greillier, L., Mastroianni, B., Decroisette, C., Schott, R., Le Moulec, S., Arrondeau, J., Cortot, A. B., Geriniere, L., Renault, A., Daniel, C., Falchero, L., and Chouaid, C. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation. *Lung Cancer*. 2019;127:96-102.
I.F.: 4.702
7. Badalamenti,G., Fanale, D., Incorvaia, L., Barraco, N., Listi, A., Maragliano, R., Vincenzi, B., Calo, V., Iovanna, J. L., Bazan, V., and Russo, A. Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? *Cell Immunol*. 2019;343:103753
I.F.: 4.078
8. Baldock,R.A., Pressimone, C. A., Baird, J. M., Khodakov, A., Luong, T. T., Grundy, M. K., Smith, C. M., Karpenshif, Y., Bratton-Palmer, D. S., Prakash, R., Jasin, M., Garcin, E. B., Gon, S., Modesti, M., and Bernstein, K. A. RAD51D splice variants and cancer-associated mutations reveal XRCC2 interaction to be critical for homologous recombination. *DNA Repair (Amst)*. 2019;76:99-107.
I.F.: 3.339
9. Ballester,P.J. Machine Learning for Molecular Modelling in Drug Design. *Biomolecules*. 2019;9:E216
I.F.: 4.082
10. Ballester,P.J. Selecting machine-learning scoring functions for structure-based virtual screening. *Drug Discov Today Technol*. 2019;32-33:81-87.
I.F.: 0
11. Balzano,M., De Grandis, M., Vu Manh, T. P., Chasson, L., Bardin, F., Farina, A., Serge, A., Bidaut, G., Charbord, P., Herault, L., Bailly, A. L., Cartier-Michaud, A., Boned, A., Dalod, M., Duprez, E., Genever, P., Coles, M., Bajenoff, M., Xerri, L., Aurrand-

Lions, M., Schiff, C., and Mancini, S. J. C. Nidogen-1 Contributes to the Interaction Network Involved in Pro-B Cell Retention in the Peri-sinusoidal Hematopoietic Stem Cell Niche. *Cell Rep.* 2019;26:3257-3271.

I.F.: 8.109

12. Barroso-Gonzalez, J., Garcia-Exposito, L., Hoang, S. M., Lynskey, M. L., Roncaioli, J. L., Ghosh, A., Wallace, C. T., Modesti, M., Bernstein, K. A., Sarkar, S. N., Watkins, S. C., and O'Sullivan, R. J. RAD51AP1 Is an Essential Mediator of Alternative Lengthening of Telomeres. *Mol Cell.* 2019;76:11-26.e7.

I.F.: 15.584

13. Barroso-Gonzalez, J., Garcia-Exposito, L., Hoang, S. M., Lynskey, M. L., Roncaioli, J. L., Ghosh, A., Wallace, C. T., Modesti, M., Bernstein, K. A., Sarkar, S. N., Watkins, S. C., and O'Sullivan, R. J. RAD51AP1 Is an Essential Mediator of Alternative Lengthening of Telomeres - Erratum. *Mol Cell.* 2019;76:217

I.F.: 15.584

14. Basse, C., Italiano, A., Penel, N., Mir, O., Chemin, C., Toulmonde, M., Duffaud, F., Le Cesne, A., Chevreau, C., Maynou, C., Anract, P., Gouin, F., Rios, M., Firmin, N., Kurtz, J. E., Kerbrat, P., Piperno-Neumann, S., Bertucci, F., Rosset, P., Isambert, N., Bompas, E., Dubray-Longeras, P., Fiorenza, F., Le Maignan, C., Chaigneau, L., Thyss, A., Bouche, O., Eymard, J. C., Lair, C. D., Adam, J., Karanian, M., Lebbe, C., Dupre, A., Meeus, P., Brahmi, M., Dufresne, A., Ducimetiere, F., Ray-Coquard, I., and Blay, J. Y. Sarcomas in patients over 90: natural history and treatment. A nationwide study over 6 years. *Int J Cancer.* 2019;145:2135-2143.

I.F.: 5.145

15. Beau-Faller, M., Pencreach, E., Leduc, C., Blons, H., Merlio, J. P., Bringuier, P. P., de Fraipont, F., Escande, F., Lemoine, A., Ouafik, L., Denis, M., Hofman, P., Lacave, R., Melaabi, S., Langlais, A., Missy, P., Morin, F., Moro-Sibilot, D., Barlesi, F., and Cadranel, J. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project. *Lung Cancer.* 2019;140:19-26.

I.F.: 4.702

16. Bertucci, A., Guiramand, J., Mescam, L., Monneur, A., Bisbal, M., Chow-Chine, L., Sannini, A., Perrot, D., De Luca, V., Mokart, D., and Bertucci, F. Successful Imatinib Treatment of an Abdominal Compartment Syndrome due to Huge Gastrointestinal Stromal Tumour. *Case Rep Oncol.* 2019;12:644-649.

I.F.: 0

17. Bertucci, F., Ng, C. K. Y., Patsouris, A., Droin, N., Piscuoglio, S., Carbuccia, N., Soria, J. C., Dien, A. T., Adnani, Y., Kamal, M., Garnier, S., Meurice, G., Jimenez, M., Dogan, S., Verret, B., Chaffanet, M., Bachelot, T., Campone, M., Lefeuvre, C., Bonnefoi, H., Dalenc, F., Jacquet, A., De Filippo, M. R., Babbar, N., Birnbaum, D., Filleron, T., Le Tourneau, C., and Andre, F. Author Correction: Genomic characterization of metastatic breast cancers. *Nature.* 2019;572:E7

I.F.: 42.778

18. Bertucci, F., Ng, C. K. Y., Patsouris, A., Droin, N., Piscuoglio, S., Carbuccia, N., Soria, J. C., Dien, A. T., Adnani, Y., Kamal, M., Garnier, S., Meurice, G., Jimenez, M., Dogan, S., Verret, B., Chaffanet, M., Bachelot, T., Campone, M., Lefeuvre, C., Bonnefoi, H., Dalenc, F., Jacquet, A., De Filippo, M. R., Babbar, N., Birnbaum, D., Filleron, T., Le Tourneau, C., and Andre, F. Genomic characterization of metastatic breast cancers. *Nature.* 2019;569:560-564.

I.F.: 42.778

19. Bertucci, F., Le Corroller-Soriano, A. G., Monneur-Miramón, A., Moulin, J. F., Fluzin, S., Maraninchi, D., and Goncalves, A. Outpatient Cancer Care Delivery in the Context of E-Oncology: A French Perspective on "Cancer outside the Hospital Walls". *Cancers (Basel).* 2019;11:E219

I.F.: 6.126

20. Bertucci, F., Finetti, P., Monneur, A., Perrot, D., Chevreau, C., Le Cesne, A., Blay, J. Y., Mir, O., and Birnbaum, D. PARP1 expression in soft tissue sarcomas is a poor-prognosis factor and a new potential therapeutic target. *Mol Oncol.* 2019;13:1577-1588.

I.F.: 6.574

21. Bertucci, F., Finetti, P., Monneur, A., and Birnbaum, D. Pathological grade-independent prediction of chemosensitivity by CINSARC should rehabilitate adjuvant chemotherapy in soft tissue sarcomas of any grade. *Ann Oncol.* 2019;30:342-343.
I.F.: 18.274
22. Besse, B., Barlesi, F., Demedts, I., Fuentes Pradera, J., Robinet, G., Gazzah, A., Soldatenkova, V., Frimodt-Moller, B., Kim, J. S., and Vansteenkiste, J. A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer. *Lung Cancer.* 2019;137:136-143.
I.F.: 4.702
23. Bian, B., Juiz, N. A., Gayet, O., Bigonnet, M., Brandone, N., Roques, J., Cros, J., Wang, N., Duseti, N., and Iovanna, J. L. Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi). *Front Oncol.* 2019;9:475
I.F.: 4.848
24. Bian, B., Fanale, D., Duseti, N., Roque, J., Pastor, S., Chretien, A. S., Incorvaia, L., Russo, A., Olive, D., and Iovanna, J. L. Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. *Oncoimmunology.* 2019;8:e1561120
I.F.: 5.869
25. Bidan, N., Bailleul-Dubois, J., Duval, J., Winter, M., Denoulet, M., Hannebicque, K., El-Sayed, I. Y., Ginestier, C., Forissier, V., Matsunaga, Y., Meignan, S., Anquez, F., Julien, S., Bonnefond, A., Derhourhi, M., Bourhis, X. L., and Lagadec, C. Transcriptomic Analysis of Breast Cancer Stem Cells and Development of a pALDH1A1:mNeptune Reporter System for Live Tracking. *Proteomics.* 2019;19:e1800454
I.F.: 3.106
26. Billon, E., Finetti, P., Bertucci, A., Niccoli, P., Birnbaum, D., Mamessier, E., and Bertucci, F. PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma. *Oncoimmunology.* 2019;8:e1655362
I.F.: 5.869
27. Bilous, M., Serdjebi, C., Boyer, A., Tomasini, P., Pouypoudat, C., Barbolosi, D., Barlesi, F., Chomy, F., and Benzekry, S. Quantitative mathematical modeling of clinical brain metastasis dynamics in non-small cell lung cancer. *Sci Rep.* 2019;9:13018
I.F.: 3.998
28. Birnbaum, D. J., Bertucci, F., Finetti, P., Birnbaum, D., and Mamessier, E. Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors. *Cancers (Basel).* 2019;11:E497
I.F.: 6.126
29. Birnbaum, D. J., Finetti, P., Birnbaum, D., Mamessier, E., and Bertucci, F. XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma. *J Clin Med.* 2019;8:E596
I.F.: 5.688
30. Blasco, M. T., Navas, C., Martin-Serrano, G., Grana-Castro, O., Lechuga, C. G., Martin-Diaz, L., Djurec, M., Li, J., Morales-Cacho, L., Esteban-Burgos, L., Perales-Paton, J., Bousquet-Mur, E., Castellano, E., Jacob, H. K. C., Cabras, L., Musteanu, M., Drost, M., Ortega, S., Mulero, F., Sainz, B., Jr., Duseti, N., Iovanna, J. L., Sanchez-Bueno, F., Hidalgo, M., Khiabani, H., Rabadan, R., Al-Shahrour, F., Guerra, C., and Barbacid, M. Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF. *Cancer Cell.* 2019;35:573-587.
I.F.: 26.602
31. Blay, J. Y., Honore, C., Stoeckle, E., Meeus, P., Jafari, M., Guin, F., Anract, P., Ferron, G., Rochwerger, A., Ropars, M., Carrere, S., Marchal, F., Sirveaux, F., Di Marco, A., Le Nail, L. R., Guiramand, J., Vaz, G., Machiavello, J. C., Marco, O., Causeret, S., Gimbergues, P., Fiorenza, F., Chaigneau, L., Guillemin, F., Guilloit, J. M., Dujardin, F., Spano, J. P., Ruzic, J. C., Michot, A., Soibinet, P., Bompas, E., Chevreau, C., Duffaud, F., Rios, M., Perrin, C., Firmin, N., Bertucci, F., Le Pechoux, C., Le Loarer, F., Collard, O., Karanian-Philippe, M., Brahmi, M., Dufresne, A., Dupre, A., Ducimetiere, F., Giraud, A., Perol, D., Toulmonde, M., Ray-Coquard, I., Italiano, A., Le Cesne, A., Penel, N., and Bonvalot, S. Surgery in reference centers improves survival of sarcoma patients: a nationwide study. *Ann Oncol.* 2019;30:1143-1153.

I.F.: 18.274

32. Blay, J. Y., Honore, C., Stoeckle, E., Meeus, P., Jafari, M., Guoin, F., Anract, P., Ferron, G., Rochwerger, A., Ropars, M., Carrere, S., Marchal, F., Sirveaux, F., Di Marco, A., Le Nail, L. R., Guiramand, J., Vaz, G., Machiavello, J. C., Marco, O., Causeret, S., Gimbergues, P., Fiorenza, F., Chaigneau, L., Guillemin, F., Guilloit, J. M., Dujardin, F., Spano, J. P., Ruzic, J. C., Michot, A., Soibinet, P., Bompas, E., Chevreau, C., Duffaud, F., Rios, M., Perrin, C., Firmin, N., Bertucci, F., Le Pechoux, C., Le Loarer, F., Collard, O., Karanian-Philippe, M., Brahmi, M., Dufresne, A., Dupre, A., Ducimetiere, F., Giraud, A., Perol, D., Toulmonde, M., Ray-Coquard, I., Italiano, A., Le Cesne, A., Penel, N., and Bonvalot, S. Surgery in reference centers improves survival of sarcoma patients: a nationwide study. *Ann Oncol.* 2019;30:1407

I.F.: 18.274

33. Blin, M., Le Tallec, B., Nahse, V., Schmidt, M., Brossas, C., Millot, G. A., Prioleau, M. N., and Debatisse, M. Transcription-dependent regulation of replication dynamics modulates genome stability. *Nat Struct Mol Biol.* 2019;26:58-66.

I.F.: 11.980

34. Blin, M. G., Bachelier, R., Fallague, K., Moussouni, K., Aurrand-Lions, M., Fernandez, S., Guillet, B., Robert, S., Foucault-Bertaud, A., Bardin, N., Blot-Chabaud, M., Dignat-George, F., and Leroyer, A. S. CD146 deficiency promotes plaque formation in a mouse model of atherosclerosis by enhancing RANTES secretion and leukocyte recruitment. *J Mol Cell Cardiol.* 2019;130:76-87.

I.F.: 5.055

35. Bomane, A., Goncalves, A., and Ballester, P. J. Paclitaxel Response Can Be Predicted With Interpretable Multi-Variate Classifiers Exploiting DNA-Methylation and miRNA Data. *Front Genet.* 2019;10:1041

I.F.: 3.260

36. Bonnefoy, N., Olive, D., and Vanhove, B. Les futures générations d'anticorps modulateurs des points de contrôle de la réponse immunitaire. *Med Sci (Paris).* 2019;35:966-974.

I.F.: 0.692

37. Borazjani, N., Sepehri, S., Behzadi, M., Jarrahpour, A., Rad, J. A., Sasanipour, M., Mohkam, M., Ghasemi, Y., Akbarizadeh, A. R., Digiorgio, C., Brunel, J. M., Ghanbari, M. M., Batta, G., and Turos, E. Three-component synthesis of chromeno beta-lactam hybrids for inflammation and cancer screening. *Eur J Med Chem.* 2019;179:389-403.

I.F.: 5.572

38. Bouabdallah, I., Thomas, P. A., and D'Journo, X. B. Recurrence in complete responders after trimodality therapy in esophageal cancer. *J Thorac Dis.* 2019;11:S1304-S1306.

I.F.: 2.027

39. Brosseau, S., Danel, C., Scherpereel, A., Mazieres, J., Lantuejoul, S., Margery, J., Greillier, L., Audigier-Valette, C., Gounant, V., Antoine, M., Moro-Sibilot, D., Rouquette, I., Molinier, O., Corre, R., Monnet, I., Langlais, A., Morin, F., Bergot, E., Zalcman, G., and Levallet, G. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort. *Clin Lung Cancer.* 2019;20:e564-e575.

I.F.: 3.550

40. Bulot, S., Audebert, S., Pieulle, L., Seduk, F., Baudalet, E., Espinosa, L., Pizay, M. C., Camoin, L., and Magalon, A. Clustering as a Means To Control Nitrate Respiration Efficiency and Toxicity in *Escherichia coli*. *MBio.* 2019;10:e01832-19

I.F.: 6.747

41. Burlion, A., Ramos, R. N., Kc, P., Sendeyo, K., Corneau, A., Menetrier-Caux, C., Piaggio, E., Olive, D., Caux, C., and Marodon, G. A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system. *Oncoimmunology.* 2019;8:1596005

I.F.: 5.869

42. Cabrie,A., Guittet, O., Tomasini, R., Vincendeau, P., and Lepoivre, M. Crosstalk between TAp73 and TGF-beta in fibroblast regulates iNOS expression and Nrf2-dependent gene transcription. *Free Radic Biol Med.* 2019;134:617-629.
I.F.: 5.657
43. Carmona,S., Brunel, J. M., Bonier, R., Sbarra, V., Robert, S., Borentain, P., Lombardo, D., Mas, E., and Gerolami, R. A squalamine derivative, NV669, as a novel PTP1B inhibitor: in vitro and in vivo effects on pancreatic and hepatic tumor growth. *Oncotarget.* 2019;10:6651-6667.
I.F.: 0
44. Casassa,E.A., Mailhol, C., Tournier, E., Laurent, C., Degboe, Y., Eischen, M., Kirsten, N., Moreau, J., Evrard, S. M., Mansat-De Mas, V., Lamant, L., Dubreuil, P., Apoil, P. A., Hermine, O., Paul, C., and Bulai Livideanu, C. Mast cell activation syndrome: High frequency of skin manifestations and anaphylactic shock. *Allergol Int.* 2019;68:119-121.
I.F.: 4.806
45. Cauchy,P., Kahn-Perles, B., Ferrier, P., Imbert, J., and Lecine, P. 2HybridTools, a handy software to facilitate clone identification and mutation mapping from yeast two-hybrid screening 6800. *PeerJ.* 2019;7:e7245
I.F.: 2.379
46. Centanni,M., Moes, D. J. A. R., Troconiz, I. F., Ciccolini, J., and van Hasselt, J. G. C. Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. *Clin Pharmacokinet.* 2019;58:835-857.
I.F.: 4.604
47. Chames,P. and Wurch, T. Les anticorps et scaffold bispécifiques, des médicaments innovants en oncologie impliquant le ciblage des cellules immunitaires. *Med Sci (Paris).* 2019;35:1072-1082.
I.F.: 0.692
48. Chanier,T. and Chames, P. Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer. *Antibodies (Basel).* 2019;8:E13
I.F.: 0
49. Chraa,D., Naim, A., Olive, D., and Badou, A. T lymphocyte subsets in cancer immunity: Friends or foes. *J Leukoc Biol.* 2019;105:243-255.
I.F.: 3.757
50. Chretien,A.S., Fauriat, C., Orlanducci, F., Rey, J., Borg, G. B., Gautherot, E., Granjeaud, S., Demerle, C., Hamel, J. F., Cerwenka, A., von Strandmann, E. P., Ifrah, N., Lacombe, C., Cornillet-Lefebvre, P., Delaunay, J., Toubert, A., Arnoulet, C., Vey, N., and Olive, D. Correction: NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia. *Oncotarget.* 2019;10:5493
I.F.: 0
51. Ciccolini,J., Barbolosi, D., Andre, N., Benzekry, S., and Barlesi, F. Combinatorial Immunotherapy Strategies: most Gods throw Dice, but fate plays Chess. *Ann Oncol.* 2019;30:1690-1691.
I.F.: 18.274
52. Couderc,A.L., Nouguerede, E., Baumstarck, K., Loubiere, S., Le Caer, H., Guillem, O., Rousseau, F., Greillier, L., Norguet-Monnereau, E., Cecile, M., Boulhassass, R., Le Caer, F., Tournier, S., Butaud, C., Guillet, P., Nahon, S., Kirscher, S., Diaz, N., Morando, C., Villani, P., Auquier, P., and Daumas, A. PREDOMOS study, impact of a social intervention program for socially isolated elderly cancer patients: update to the study protocol for a randomized controlled trial. *Trials.* 2019;20:54
I.F.: 1.883
53. Couraud,S., Barlesi, F., Fontaine-Deraluelle, C., Debieuvre, D., Merlio, J. P., Moreau, L., Beau-Faller, M., Veillon, R., Mosser, J., Al Freijjat, F., Bringuier, P. P., Lena, H., Ouafik, L., Westeel, V., Morel, A., Audigier-Valette, C., Missy, P., Langlais, A., Morin, F., Souquet, P. J., and Planchard, D. Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study. *Eur J Cancer.* 2019;116:86-97.

I.F.: 7.275

54. Couturier-Maillard,A., Froux, N., Piotet-Morin, J., Michaudel, C., Brault, L., Le Berichel, J., Senechal, A., Robinet, P., Chenuet, P., Jejou, S., Dumoutier, L., Renauld, J. C., Iovanna, J. L., Huber, S., Chamaillard, M., Quesniaux, V. F. J., Sokol, H., and Ryffel, B. Correction: Interleukin-22-deficiency and microbiota contribute to the exacerbation of *Toxoplasma gondii*-induced intestinal inflammation. *Mucosal Immunol.* 2019;12:290

I.F.: 7.352

55. Dalle Vedove,A., Falchi, F., Donini, S., Dobric, A., Germain, S., Di Martino, G. P., Prosdocimi, T., Vettraiño, C., Torretta, A., Cavalli, A., Rigot, V., Andre, F., and Parisini, E. Structure-Based Virtual Screening Allows the Identification of Efficient Modulators of E-Cadherin-Mediated Cell-Cell Adhesion. *Int J Mol Sci.* 2019;20:E3404

I.F.: 4.556

56. Daulat,A.M., Finetti, P., Revinski, D., Silveira Wagner, M., Camoin, L., Audebert, S., Birnbaum, D., Kodjabachian, L., Borg, J. P., and Bertucci, F. ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer. *Br J Cancer.* 2019;120:931-940.

I.F.: 5.791

57. Daulat,A.M., Wagner, M. S., Walton, A., Baudalet, E., Audebert, S., Camoin, L., and Borg, J. P. The Tumor Suppressor SCRIB is a Negative Modulator of the Wnt/beta-Catenin Signaling Pathway. *Proteomics.* 2019;19:e1800487

I.F.: 3.106

58. de Groot,A., Siponen, M. I., Magerand, R., Eugenie, N., Martin-Arevalillo, R., Doloy, J., Lemaire, D., Brandelet, G., Parcy, F., Dumas, R., Roche, P., Servant, P., Confalonieri, F., Arnoux, P., Pignol, D., and Blanchard, L. Crystal structure of the transcriptional repressor DdrO: insight into the metalloprotease/repressor-controlled radiation response in *Deinococcus*. *Nucleic Acids Res.* 2019;47:11403-11417.

I.F.: 11.502

59. de Nonneville,A., Finetti, P., Adelaide, J., Lambaudie, E., Viens, P., Goncalves, A., Birnbaum, D., Mamessier, E., and Bertucci, F. A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers. *Cancers (Basel).* 2019;11:E1158

I.F.: 6.126

60. de Nonneville,A., Barbolosi, D., Andriantsoa, M., El-Cheikh, R., Duffaud, F., Bertucci, F., and Salas, S. Validation of Neutrophil Count as An Algorithm-Based Predictive Factor of Progression-Free Survival in Patients with Metastatic Soft Tissue Sarcomas Treated with Trabectedin. *Cancers (Basel).* 2019;11:E432

I.F.: 6.126

61. Degboe,Y., Eischen, M., Apoil, P. A., Mailhol, C., Dubreuil, P., Hermine, O., Paul, C., Bulai Livideanu, C., and Laroche, M. Higher prevalence of vertebral fractures in systemic mastocytosis, but not in cutaneous mastocytosis and idiopathic mast cell activation syndrome. *Osteoporos Int.* 2019;30:1235-1241.

I.F.: 3.864

62. Degos,C., Heinemann, M., Barrou, J., Boucherit, N., Lambaudie, E., Savina, A., Gorvel, L., and Olive, D. Endometrial Tumor Microenvironment Alters Human NK Cell Recruitment, and Resident NK Cell Phenotype and Function. *Front Immunol.* 2019;10:877-I.F.: 5.085

63. Del Bano,J., Flores-Flores, R., Josselin, E., Goubard, A., Ganier, L., Castellano, R., Chames, P., Baty, D., and Kerfelec, B. A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer. *Front Immunol.* 2019;10:1593-I.F.: 5.085

64. Delteil,C., Macagno, N., Daniel, L., D'Journo, X. B., Guisiano, S., Garcia, S., and Secq, V. Léiomyomatose œsophagienne diffuse et syndrome d'Alport : rapport d'un cas. *Ann Pathol.* 2019;39:36-39.

I.F.: 0.394

65. Desmedt,C., Pingitore, J., Rothe, F., Marchio, C., Clatot, F., Rouas, G., Richard, F., Bertucci, F., Mariani, O., Galant, C., Fribbens, C., O'Leary, B., Van den Eynden, G., Salgado, R., Turner, N. C., Piccart, M., Vincent-Salomon, A., Pruneri, G., Larsimont, D., and Sotiriou, C. ESR1 mutations in metastatic lobular breast cancer patients. *NPJ Breast Cancer*. 2019;5:9
I.F.: 6.000
66. Deyme,L., Barbolosi, D., and Gattacceca, F. Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters. *Cancer Chemother Pharmacol*. 2019;83:27-42.
I.F.: 2.967
67. Ding,L., Lyu, Z., Tintaru, A., Laurini, E., Marson, D., Louis, B., Bouhlel, A., Balasse, L., Fernandez, S., Garrigue, P., Mas, E., Giorgio, S., Pricl, S., Guillet, B., and Peng, L. A self-assembling amphiphilic dendrimer nanotracer for SPECT imaging. *Chem Commun (Camb)*. 2019;56:301-304.
I.F.: 5.996
68. Donnette,M., Solas, C., Giocanti, M., Venton, G., Farnault, L., Berda-Haddad, Y., Hau, L. T. T., Costello, R., Ouafik, L., Lacarelle, B., Ciccolini, J., and Fanciullino, R. Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in LAM patients. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2019;1126-1127:121770
I.F.: 3.004
69. Dubois,C., Pophillat, M., Audebert, S., Fourquet, P., Lecomte, C., Dubourg, N., Galas, S., Camoin, L., and Frelon, S. Differential modification of the *C. elegans* proteome in response to acute and chronic gamma radiation: Link with reproduction decline. *Sci Total Environ*. 2019;676:767-781.
I.F.: 5.589
70. Duhoo,Y., Girault, V., Turchetto, J., Ramond, L., Durbesson, F., Fourquet, P., Nomine, Y., Cardoso, V., Sequeira, A. F., Bras, J. L. A., Fontes, C. M. G. A., Trave, G., Wolff, N., and Vincentelli, R. High-Throughput Production of a New Library of Human Single and Tandem PDZ Domains Allows Quantitative PDZ-Peptide Interaction Screening Through High-Throughput Holdup Assay. *Methods Mol Biol*. 2019;2025:439-476.
I.F.: 0
71. Dustin,M.L., Scotet, E., and Olive, D. An X-ray Vision for Phosphoantigen Recognition. *Immunity*. 2019;50:1026-1028.
I.F.: 22.553
72. Estaras,M., Moreno, N., Santofimia-Castano, P., Martinez-Morcillo, S., Roncero, V., Blanco, G., Lopez, D., Fernandez-Bermejo, M., Mateos, J. M., Iovanna, J. L., Salido, G. M., and Gonzalez, A. Melatonin induces reactive oxygen species generation and changes in glutathione levels and reduces viability in human pancreatic stellate cells. *J Physiol Biochem*. 2019;75:185-197
I.F.: 2.523
73. Farnault,L., Venton, G., Pourroy, B., Jourde-Chiche, N., Ivanov, V., Arcani, R., Roche, P., Mercier, C., Colle, J., Fanciullino, R., and Costello, R. T. Severe renal insufficiency is not an absolute pitfall to autologous stem cell transplantation with BeEAM (bendamustine, etoposide, cytarabine, melphalan) conditioning regimen. *Bone Marrow Transplant*. 2019;54:1173-1175.
I.F.: 4.725
74. Fouque,A., Delalande, O., Jean, M., Castellano, R., Josselin, E., Malleter, M., Shoji, K. F., Hung, M. D., Rampanarivo, H., Collette, Y., van de Weghe, P., and Legembre, P. Correction to A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells. *J Med Chem*. 2019;62:9339-9340.
I.F.: 6.054
75. Fradet,M., Negretto, M., Tournier, E., Laurent, C., Apoil, P. A., Evrard, S., Degboe, Y., Del Mas, V., Lamant, L., Dubreuil, P., Laroche, M., Mailhol, C., Hermine, O., Paul, C., and Bulai Livideanu, C. Frequency of isolated cutaneous involvement in adult mastocytosis: a cohort study. *J Eur Acad Dermatol Venereol*. 2019;33:1713-1718.
I.F.: 5.113



76. Frankel,D., Bourlard, D., Garcia, S., Robaglia-Schlupp, A., Peker, E., Groliere, A., Kaspi, E., and Roll, P. Mise en évidence du réarrangement d'ALK et ROS1 en immunocytochimie sur liquides de ponction. *Ann Pathol.* 2019;39:227-236.
I.F.: 0.394
77. Frit,P., Ropars, V., Modesti, M., Charbonnier, J. B., and Calsou, P. Plugged into the Ku-DNA hub: The NHEJ network. *Prog Biophys Mol Biol.* 2019;147:62-76.
I.F.: 2.703
78. Garciaz,S., N'guyen Dasi, L., Finetti, P., Chevalier, C., Vernerey, J., Poplineau, M., Platet, N., Audebert, S., Pophillat, M., Camoin, L., Bertucci, F., Calmels, B., Recher, C., Birnbaum, D., Chabannon, C., Vey, N., and Duprez, E. Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation. *Clin Epigenetics.* 2019;11:141
I.F.: 6.091
79. Garcin,E.B., Gon, S., Sullivan, M. R., Brunette, G. J., Cian, A., Concordet, J. P., Giovannangeli, C., Dirks, W. G., Eberth, S., Bernstein, K. A., Prakash, R., Jasin, M., and Modesti, M. Differential Requirements for the RAD51 Paralogs in Genome Repair and Maintenance in Human Cells. *PLoS Genet.* 2019;15:e1008355
I.F.: 5.224
80. Gbeto,C.C., Quaranta, S., Mari, R., Fanciullino, R., Roche, C., Nahon, S., Solas, C., Ouafik, L., Lacarelle, B., Allegre, T., and Ciccolini, J. Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryrimidine dehydrogenase deficiency. *Pharmacogenomics.* 2019;20:931-938.
I.F.: 2.339
81. Goehrig,D., Nigri, J., Samain, R., Wu, Z., Cappello, P., Gabiane, G., Zhang, X., Zhao, Y., Kim, I. S., Chanal, M., Curto, R., Hervieu, V., de La Fouchardiere, C., Novelli, F., Milani, P., Tomasini, R., Bousquet, C., Bertolino, P., and Hennino, A. Stromal protein betaig-h3 reprogrammes tumour microenvironment in pancreatic cancer. *GUT.* 2019;68:693-707.
I.F.: 19.819
82. Gonzalez,C., Chames, P., Kerfelec, B., Baty, D., Robert, P., and Limozin, L. Nanobody-CD16 Catch Bond Reveals NK Cell Mechanosensitivity. *Biophys J.* 2019;116:1516-1526.
I.F.: 3.854
83. Guerder,S., Hassel, C., and Carrier, A. Thymus-specific serine protease, a protease that shapes the CD4 T cell repertoire. *Immunogenetics.* 2019;71:223-232.
I.F.: 2.621
84. Guiseppi,A., Vicente, J. J., Herrou, J., Byrne, D., Barneoud, A., Moine, A., Espinosa, L., Basse, M. J., Molle, V., Mignot, T., Roche, P., and Mauriello, E. M. F. A divergent CheW confers plasticity to nucleoid-associated chemosensory arrays. *PLoS Genet.* 2019;15:e1008533
I.F.: 5.224
85. Hellmann,M.D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S. W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., Sakai, H., Albert, I., Vergnenegre, A., Peters, S., Syrigos, K., Barlesi, F., Reck, M., Borghaei, H., Brahmer, J. R., O'Byrne, K. J., Geese, W. J., Bhagavatheeswaran, P., Rabindran, S. K., Kasinathan, R. S., Nathan, F. E., and Ramalingam, S. S. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. *N Engl J Med.* 2019;381:2020-2031.
I.F.: 74.699
86. Heng-Maillard,M.A., Verschuur, A., Aschero, A., Dabadie, A., Jouve, E., Chastagner, P., Leblond, P., Aerts, I., De Luca, B., and Andre, N. SFCE METRO-01 four-drug metronomic regimen phase II trial for pediatric extracranial tumor. *Pediatr Blood Cancer.* 2019;e27693
I.F.: 2.355
87. Hernandez,J., Hoffer, L., Coutard, B., Querat, G., Roche, P., Morelli, X., Decroly, E., and Barral, K. Optimization of a fragment linking hit toward Dengue and Zika virus NS5 methyltransferases inhibitors. *Eur J Med Chem.* 2019;161:323-333.

I.F.: 5.572

88. Heskamp,S., Wierstra, P. J., Molkenboer-Kuennen, J. D., Sandker, G. W., Thordardottir, S., Cany, J., Olive, D., Bussink, J., Boerman, O. C., Dolstra, H., Aarntzen, E. H. J. G., and Hobo, W. PD-L1 microSPECT/CT imaging for longitudinal monitoring of PD-L1 expression in syngeneic and humanized mouse models for cancer. *Cancer Immunol Res.* 2019;7:150-161.

I.F.: 8.728

89. Hoffer,L., Saez-Ayala, M., Horvath, D., Varnek, A., Morelli, X., and Roche, P. Covadots: In Silico Chemistry-Driven Tool to Design Covalent Inhibitors Using a Linking Strategy. *J Chem Inf Model.* 2019;59:1472-1485.

I.F.: 3.966

90. Hofman,P. and Barlesi, F. Companion diagnostic tests for treatment of lung cancer patients: what are the current and future challenges? *Expert Rev Mol Diagn.* 2019;19:429-438.

I.F.: 4.096

91. Honore,C., Delhorme, J. B., Nassif, E., Faron, M., Ferron, G., Bompas, E., Glehen, O., Italiano, A., Bertucci, F., Orbach, D., Pocard, M., Quenet, F., Blay, J. Y., Carrere, S., Chevreau, C., Mir, O., and Le Cesne, A. Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients. *Surg Oncol.* 2019;29:107-112.

I.F.: 2.521

92. Huang,C., Lan, W., Fraunhoffer, N., Meilerman, A., Iovanna, J., and Santofimia-Castano, P. Dissecting the Anticancer Mechanism of Trifluoperazine on Pancreatic Ductal Adenocarcinoma. *Cancers (Basel).* 2019;11:E1869

I.F.: 6.126

93. Incorvaia,L., Badalamenti, G., Rinaldi, G., Iovanna, J. L., Olive, D., Swayden, M., Terruso, L., Vincenzi, B., Fulfaro, F., Bazan, V., Russo, A., and Fanale, D. Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma? *Ther Adv Med Oncol.* 2019;11:1-15.

I.F.: 6.852

94. Janssens,G.O., Timmermann, B., Laprie, A., Mandeville, H., Padovani, L., Chargari, C., Journy, N., Kameric, L., Kienesberger, A., Brunhofer, M., Kozhaeva, O., Gasparotto, C., Kearns, P., Boterberg, T., Lievens, Y., and Vassal, G. Recommendations for the organisation of care in paediatric radiation oncology across Europe: a SIOPE-ESTRO-PROS-CCI-Europe collaborative project in the framework of the JARC. *Eur J Cancer.* 2019;114:47-54.

I.F.: 7.275

95. Jeanson,A., Tomasini, P., Souquet-Bressand, M., Brandone, N., Boucekine, M., Grangeon, M., Chaleat, S., Khobta, N., Milia, J., Mhanna, L., Greillier, L., Biemar, J., Nanni, I., Ouafik, L., Garcia, S., Mazieres, J., Barlesi, F., and Mascaux, C. Brief report: efficacy of immune checkpoint inhibitors in KRAS-mutant Non-small cell lung cancer (NSCLC). *J Thorac Oncol.* 2019;14:1095-1101.

I.F.: 13.357

96. Jeanson,A., Boyer, A., Greillier, L., Tomasini, P., and Barlesi, F. Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer. *Expert Rev Anticancer Ther.* 2019;19:11-17.

I.F.: 3.573

97. Juanes,M.A., Isnardon, D., Badache, A., Brasselet, S., Mavrakis, M., and Goode, B. L. The role of APC-mediated actin assembly in microtubule capture and focal adhesion turnover. *J Cell Biol.* 2019;218:3415-3435.

I.F.: 8.891

98. Juiz,N.A., Iovanna, J. L., and Dusetti, N. Pancreatic Cancer Heterogeneity Can Be Explained Beyond the Genome. *Front Oncol.* 2019;9:246

I.F.: 4.848

99. Jung, K.H., LoRusso, P. M., Burris, H. A., Gordon, M. S., Bang, Y. J., Hellmann, M. D., Cervantes, A., Ochoa de Olza, M., Marabelle, A., Hodi, F. S., Ahn, M. J., Emens, L. A., Barlesi, F., Hamid, O., Calvo, E., McDermott, D. F., Soliman, H., Rhee, I., Lin, R., Pourmohamad, T., Suhomel, J., Tshako, A., Morrissey, K. M., Mahrus, S., Morley, R., Pirzkall, A., and Davis, S. L. Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. *Clin Cancer Res.* 2019;25:3220-3228.
I.F.: 10.107
100. Karkeni, E., Morin, S. O., Bou Tayeh, B., Goubard, A., Josselin, E., Castellano, R., Fauriat, C., Guittard, G., Olive, D., and Nunes, J. A. Vitamin D Controls Tumor Growth and CD8+ T Cell Infiltration in Breast Cancer. *Front Immunol.* 2019;10:1307
I.F.: 5.085
101. Katsogiannou, M., Boyer, J. B., Valdeolivas, A., Remy, E., Calzone, L., Audebert, S., Rocchi, P., Camoin, L., and Baudot, A. Integrative proteomic and phosphoproteomic profiling of prostate cell lines. *PLoS One.* 2019;14:e0224148
I.F.: 2.740
102. Le Cesne, A., Marec-Berard, P., Blay, J. Y., Gaspar, N., Bertucci, F., Penel, N., Bompas, E., Cousin, S., Toulmonde, M., Bessedes, A., Fridman, W. H., Sautes-Fridman, C., Kind, M., Le Loarer, F., Pulido, M., and Italiano, A. Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. *Eur J Cancer.* 2019;119:151-157.
I.F.: 7.275
103. Lemal, R., Fouquet, G., Terriou, L., Vaes, M., Livideanu, C. B., Frenzel, L., Barete, S., Canioni, D., Lhermitte, L., Rossignol, J., Arock, M., Dubreuil, P., Lortholary, O., and Hermine, O. Omalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS and MCAS. *J Allergy Clin Immunol Pract.* 2019;7:2387-2395.e3.
I.F.: 7.574
104. Leveque, R., Corbet, C., Aubert, L., Guilbert, M., Lagadec, C., Adriaenssens, E., Duval, J., Finetti, P., Birnbaum, D., Magne, N., Chopin, V., Bertucci, F., Le Bourhis, X., and Toillon, R. A. ProNGF increases breast tumor aggressiveness through functional association of TrkA with EphA2. *Cancer Lett.* 2019;449:196-206.
I.F.: 7.360
105. Li, H., Peng, J., Sidorov, P., Leung, Y., Leung, K. S., Wong, M. H., Lu, G., and Ballester, P. J. Classical scoring functions for docking are unable to exploit large volumes of structural and interaction data. *Bioinformatics.* 2019;35:3989-3995.
I.F.: 5.612
106. Lions, C., Laroche, H., Zaegel-Faucher, O., Ressiot, E., Bregigeeon, S., Geneau de Lamarliere, P., Solas, C., Tamalet, C., Pieve, M. A., Ritleng, A. S., Debreux, C., Ivanova, A., Obry-Roguet, V., Carrieri, P., and Poizot-Martin, I. Hepatitis C virus-microelimination program and patient trajectories after hepatitis C virus cure in an outpatient HIV clinical unit. *Eur J Gastroenterol Hepatol.* 2019;32:1212-1221.
I.F.: 2.251
107. Lomberk, G., Dusetti, N., Iovanna, J. L., and Urrutia, R. Emerging epigenomic landscapes of pancreatic cancer in the era of precision medicine. *Nat Commun.* 2019;10:3875
I.F.: 12.121
108. Lopresti, A., Malergue, F., Bertucci, F., Liberatoscioli, M. L., Garnier, S., DaCosta, Q., Finetti, P., Gilibert, M., Raoul, J. L., Birnbaum, D., Acquaviva, C., and Mamessier, E. Sensitive and easy screening for circulating tumor cells by flow cytometry. *JCI Insight.* 2019;4:e128180
I.F.: 6.205
109. Lorient, M.A., Maskouri, F., Carni, P., Le Malicot, K., Seitz, J. F., Michel, P., Legoux, J. L., Bouche, O., Andre, T., Faroux, R., Delalogue, S., Malka, D., Guigay, J., Thariat, J., Thomas, F., Barin-Le-Guellec, C., Ciccolini, J., Boyer, J. C., and Etienne-Grimaldi, M. C. Intérêts et limites de la recherche du déficit en dihydropyrimidine déshydrogénase dans le suivi des patients traités par fluoropyrimidines : résultats de deux enquêtes nationales de pratiques réalisées auprès des médecins et des biologistes. *Bull Cancer.* 2019;106:759-775.

I.F.: 0.912

110. Madani,A., Ridenour, J. N., Martin, B. P., Paudel, R. R., Abdul Basir, A., Le Moigne, V., Herrmann, J. L., Audebert, S., Camoin, L., Kremer, L., Spilling, C. D., Canaan, S., and Cavalier, J. F. Cyclopostins and Cyclophostin analogs are multi-target inhibitors that impair growth of Mycobacterium abscessus. *ACS Infect Dis.* 2019;5:1597-1608.

I.F.: 4.614

111. Maille,E., Brosseau, S., Hanoux, V., Creveuil, C., Danel, C., Bergot, E., Scherpereel, A., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Molinier, O., Corre, R., Monnet, I., Gounant, V., Langlais, A., Morin, F., Levallet, G., and Zalzman, G. MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial. *Br J Cancer.* 2019;120:387-397.

I.F.: 5.791

112. Malissen,N., Macagno, N., Granjeaud, S., Granier, C., Moutardier, V., Gaudy-Marqueste, C., Habel, N., Mandavit, M., Guillot, B., Pasero, C., Tartour, E., Ballotti, R., Grob, J. J., and Olive, D. HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma. *Oncoimmunology.* 2019;8:e1665976

I.F.: 5.869

113. Manai,M., Finetti, P., Mejri, N., Athimni, S., Birnbaum, D., Bertucci, F., Rahal, K., Gamoudi, A., Chaffanet, M., Manai, M., and Boussen, H. Inflammatory breast cancer in 210 patients: A retrospective study on epidemiological, anatomo-clinical features and therapeutic results. *Mol Clin Oncol.* 2019;10:223-230.

I.F.: 0

114. Manai,M., Abdeljaoued, S., Goucha, A., Adouni, O., Bettaieb, I., Bouzaien, H., Rahal, K., Birnbaum, D., Bertucci, F., and Gamoudi, A. MARCKS protein overexpression is associated with poor prognosis in male breast cancer. *Cancer Biomark.* 2019;26:513-522.

I.F.: 3.436

115. Maran-Gonzalez,A., Franchet, C., Duprez-Paumier, R., Antoine, M., Barlier, C., Becette, V., Berghian, A., Blanc-Fournier, C., Brabencova, E., Charafe-Jauffret, E., Chenard, M. P., Dauplat, M. M., Delree, P., Fleury, C., Garbar, C., Ghnassia, J. P., Haudebourg, J., MacGrogan, G., Mathieu, M. C., Michenet, P., Penault-Llorca, F., Poulet, B., Robin, Y., Roger, P., Russ, E., Treilleux, I., Valent, A., Verrielle, V., Vincent-Salomon, A., Arnould, L., and Lacroix-Triki, M. Recommandations du GEFPICS pour la prise en charge des prélèvements dans le cadre du traitement néoadjuvant du cancer du sein. *Ann Pathol.* 2019;39:383-398.

I.F.: 0.394

116. Mari,R., Mamessier, E., Lambaudie, E., Provansal, M., Birnbaum, D., Bertucci, F., and Sabatier, R. Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease. *Cancers (Basel).* 2019;11:E774-I.F.: 6.126

117. Marrella,A., Dondero, A., Aiello, M., Casu, B., Olive, D., Regis, S., Bottino, C., Pende, D., Meazza, R., Caluori, G., Castriconi, R., and Scaglione, S. Cell-Laden Hydrogel as a Clinical-Relevant 3D Model for Analyzing Neuroblastoma Growth, Immunophenotype, and Susceptibility to Therapies. *Front Immunol.* 2019;10:1876

I.F.: 5.085

118. Martinez-Anton,A., Gras, D., Bourdin, A., Dubreuil, P., and Chanez, P. KIT as a therapeutic target for non-oncological diseases. *Pharmacol Ther.* 2019;197:11-37.

I.F.: 10.557

119. Maslowska,K.H., Laureti, L., and Pages, V. iDamage: a method to integrate modified DNA into the yeast genome. *Nucleic Acids Res.* 2019;47:e124

I.F.: 11.502

120. Mazieres,J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A. B., Mezquita, L., Thai, A. A., Masciaux, C., Couraud, S., Veillon, R., Van Den Heuvel, M., Neal, J., Peled, N., Fruh, M., Ng, T. L., Gounant, V., Popat, S., Diebold, J., Sabari, J., Zhu, V. W.,

- Rothschild, S. I., Bironzo, P., Martinez, A., Curioni-Fontecedro, A., Rosell, R., Lattuca-Truc, M., Wiesweg, M., Besse, B., Solomon, B., Barlesi, F., Schouten, R. D., Wakelee, H., Camidge, D. R., Zalcman, G., Novello, S., Ou, S. I., Milia, J., and Gautschi, O. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. *Ann Oncol.* 2019;30:1321-1328.
I.F.: 18.274
121. McCarron, M. J., Irla, M., Serge, A., Soudja, S. M., and Marie, J. C. Transforming Growth Factor-beta signaling in alphabeta thymocytes promotes negative selection. *Nat Commun.* 2019;10:5690-I.F.: 12.121
122. Meurer, M., Floquet, A., Ray-Coquard, I., Bertucci, F., Auriche, M., Cordoba, A., Piperno-Neumann, S., Salas, S., Delannes, M., Chevalier, T., Italiano, A., Blay, J. Y., Mancini, J., Pautier, P., and Duffaud, F. Localized high grade endometrial stromal sarcoma and localized undifferentiated uterine sarcoma: a retrospective series of the French Sarcoma Group. *Int J Gynecol Cancer.* 2019;29:691-698.
I.F.: 2.095
123. Mezouar, S., Ben Amara, A., Chartier, C., Gorvel, L., and Mege, J. L. A Fast and Reliable Method to Isolate Human Placental Macrophages. *Curr Protoc Immunol.* 2019;125:e77
I.F.: 0
124. Mezouar, S., Vitte, J., Gorvel, L., Ben Amara, A., Desnues, B., and Mege, J. L. Mast Cell Cytokines as a Defense Mechanism against *Coxiella burnetii*. *MBio.* 2019;10:e02669
I.F.: 6.747
125. Miles, D. M., Desdouets, C., and Geli, V. Histone stress: an unexplored source of chromosomal instability in cancer? *Curr Genet.* 2019;65:1081-1088.
I.F.: 3.464
126. Moeung, S., Chevreau, C., Poinsignon, V., Guitton, J., Lelievre, B., Ciccolini, J., Gladieff, L., Massart, C., Flechon, A., Delva, R., Gravis, G., Lotz, J. P., Bay, J. O., Gross-Goupil, M., Delahousse, J., Filleron, T., Lochon, I., Chatelut, E., and Thomas, F. Estimation of unbound carboplatin clearance from total plasma concentrations as a means of facilitating therapeutic drug monitoring. *Ther Drug Monit.* 2019;41:66-74.
I.F.: 2.047
127. Mogenet, A., Tomasini, P., Greillier, L., and Barlesi, F. Lorlatinib: an additional option for ALK-positive non-small cell lung cancer? *Transl Lung Cancer Res.* 2019;8:S383-S386.
I.F.: 5.132
128. Moro-Sibilot, D., Cozic, N., Perol, M., Mazieres, J., Otto, J., Souquet, P. J., Bahleda, R., Wislez, M., Zalcman, G., de Guibert, S., Barlesi, F., Mennecier, B., Monnet, I., Sabatier, R., Bota, S., Dubos, C., Verrielle, V., Haddad, V., Ferretti, G., Cortot, A., de Fraipont, F., Jimenez, M., Hoog-Labouret, N., and Vassal, G. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSe phase II trial. *Ann Oncol.* 2019;30:1985-1991.
I.F.: 18.274
129. Murat El Houdigui, S., Adam-Guillermin, C., Loro, G., Arcanjo, C., Frelon, S., Floriani, M., Dubourg, N., Baudalet, E., Audebert, S., Camoin, L., and Armant, O. A systems biology approach reveals neuronal and muscle developmental defects after chronic exposure to ionising radiation in zebrafish. *Sci Rep.* 2019;9:20241
I.F.: 3.998
130. Nakagawa, N., Plestant, C., Yabuno-Nakagawa, K., Li, J., Lee, J., Huang, C. W., Lee, A., Krupa, O., Adhikari, A., Thompson, S., Rhynes, T., Arevalo, V., Stein, J. L., Molnar, Z., Badache, A., and Anton, E. S. Memo1-Mediated Tiling of Radial Glial Cells Facilitates Cerebral Cortical Development. *Neuron.* 2019;103:836-852.e5.
I.F.: 14.415

131. Nawrotek,A., Benabdi, S., Niyomchon, S., Kryszke, M. H., Ginestier, C., Caneque, T., Tepshi, L., Mariani, A., St Onge, R. P., Giaever, G., Nislow, C., Charafe-Jauffret, E., Rodriguez, R., Zeghouf, M., and Cherfils, J. PH-domain-binding inhibitors of nucleotide exchange factor BRAG2 disrupt Arf GTPase signaling. *Nat Chem Biol.* 2019;15:358-366.
I.F.: 12.587
132. Nawrotek,A., Benabdi, S., Niyomchon, S., Kryszke, M. H., Ginestier, C., Caneque, T., Tepshi, L., Mariani, A., St Onge, R. P., Giaever, G., Nislow, C., Charafe-Jauffret, E., Rodriguez, R., Zeghouf, M., and Cherfils, J. Publisher Correction: PH-domain-binding inhibitors of nucleotide exchange factor BRAG2 disrupt Arf GTPase signaling. *Nat Chem Biol.* 2019;15:549
I.F.: 12.587
133. Neant,N., Solas, C., Bouazza, N., Le, M. P., Yazdanpanah, Y., Dhiver, C., Bregigeon, S., Mokhtari, S., Peytavin, G., Tamalet, C., Descamps, D., Lacarelle, B., and Gattacceca, F. Concentration-response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients. *J Antimicrob Chemother.* 2019;74:1992-2002.
I.F.: 5.113
134. Neira,J.L., Correa, J., Rizzuti, B., Santofimia-Castano, P., Abian, O., Velazquez-Campoy, A., Fernandez-Megia, E., and Iovanna, J. L. Dendrimers as competitors of protein-protein interactions of the intrinsically disordered nuclear chromatin protein NUPR1. *Biomacromolecules.* 2019;20:2567-2576.
I.F.: 6.092
135. Neira,J.L., Palomino-Schatzlein, M., Ricci, C., Ortore, M. G., Rizzuti, B., and Iovanna, J. L. Dynamics of the intrinsically disordered protein NUPR1 in isolation and in its fuzzy complexes with DNA and prothymosin alpha. *Biochim Biophys Acta Proteins Proteom.* 2019;1867:140252
I.F.: 2.371
136. Nicol,M., Mlouka, M. A. B., Berthe, T., Di Martino, P., Jouenne, T., Brunel, J. M., and De, E. Anti-persister activity of squalamine against *Acinetobacter baumannii*. *Int J Antimicrob Agents.* 2019;53:337-342.
I.F.: 4.621
137. Ou,S.I., Gadgeel, S. M., Barlesi, F., Yang, J. C., De Petris, L., Kim, D. W., Govindan, R., Dingemans, A. M., Crino, L., Lena, H., Popat, S., Ahn, J. S., Dansin, E., Mitry, E., Muller, B., Bordogna, W., Balas, B., Morcos, P. N., and Shaw, A. T. Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. *Lung Cancer.* 2019;139:22-27.
I.F.: 4.702
138. Overman,J., Fontaine, F., Wylie-Sears, J., Moustaqil, M., Huang, L., Meurer, M., Chiang, I. K., Lesieur, E., Patel, J., Zuegg, J., Pasquier, E., Sierrecki, E., Gambin, Y., Hamdan, M., Khosrotehrani, K., Andelfinger, G., Bischoff, J., and Francois, M. R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma. *Elife.* 2019;8:e43026
I.F.: 7.080
139. Padovani,L., Horan, G., and Ajithkumar, T. Radiotherapy Advances in Paediatric Medulloblastoma Treatment. *Clinical oncology (Royal College of Radiologists (Great Britain)).* 2019;31:171-181.
I.F.: 3.113
140. Panier,S., Maric, M., Hewitt, G., Mason-Osann, E., Gali, H., Dai, A., Labadorf, A., Guervilly, J. H., Ruis, P., Segura-Bayona, S., Belan, O., Marzec, P., Gaillard, P. H. L., Flynn, R. L., and Boulton, S. J. SLX4IP Antagonizes Promiscuous BLM Activity during ALT Maintenance. *Mol Cell.* 2019;76:27-43.e11.
I.F.: 15.584
141. Pantziarka,P. and Andre, N. Editorial: Drug Repurposing. *Front Med (Lausanne).* 2019;6:154
I.F.: 3.113
142. Pautier,P., Penel, N., Ray-Coquard, I., Italiano, A., Bompas, E., Delcambre, C., Bay, J. O., Bertucci, F., Delaye, J., Chevreau, C., Cupissol, D., Bozec, L., Eymard, J. C., Saada, E., Isambert, N., Guillemet, C., Rios, M., Piperno-Neumann, S., Chenuc, G., and

- Duffaud, F. A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study). *Eur J Cancer*. 2019;125:31-37.
I.F.: 7.275
143. Peon, A., Li, H., Ghislat, G., Leung, K. S., Wong, M. H., Lu, G., and Ballester, P. J. MolTarPred: a web tool for comprehensive target prediction with reliability estimation. *Chem Biol Drug Des*. 2019;94:1390-1401.
I.F.: 2.548
144. Peters, G. J., Giovannetti, E., Honeywell, R. J., and Ciccolini, J. Can Cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response? *Br J Clin Pharmacol*. 2019;85:1213-1214.
I.F.: 3.740
145. Peyruchaud, O., Saier, L., and Leblanc, R. Autotaxin Implication in Cancer Metastasis and Autoimmune Disorders: Functional Implication of Binding Autotaxin to the Cell Surface. *Cancers (Basel)*. 2019;12:E105
I.F.: 6.126
146. Piperno-Neumann, S., Ray-Coquard, I., Océan, B. V., Laurence, V., Cupissol, D., Perrin, C., Penel, N., Bompas, E., Rios, M., Lecesne, A., Italiano, A., Anract, P., de Pinieux, G., Collard, O., Bertucci, F., Duffaud, F., Le Deley, M. C., Delaye, J., Brugieres, L., and Blay, J. Y. Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study. *Int J Cancer*. 2019;146:413-423.
I.F.: 5.145
147. Planes-Laine, G., Rochigneux, P., Bertucci, F., Chretien, A. S., Viens, P., Sabatier, R., and Goncalves, A. PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. *Cancers (Basel)*. 2019;11:1033
I.F.: 6.126
148. Poplineau, M., Vernerey, J., Platet, N., N'Guyen, L., Herault, L., Esposito, M., Saurin, A. J., Guilouf, C., Iwama, A., and Duprez, E. PLZF limits enhancer activity during hematopoietic progenitor aging. *Nucleic Acids Res*. 2019;47:4509-4520.
I.F.: 11.502
149. Porebski, B., Wild, S., Kummer, S., Scaglione, S., Gaillard, P. H. L., and Gari, K. WRNIP1 Protects Reversed DNA Replication Forks from SLX4-Dependent Nucleolytic Cleavage. *iScience*. 2019;21:31-41.
I.F.: 4.447
150. Rathore, M., Girard, C., Ohanna, M., Tichet, M., Ben Jouira, R., Garcia, E., Larbret, F., Gesson, M., Audebert, S., Lacour, J. P., Montaudie, H., Prod'Homme, V., Tartare-Deckert, S., and Deckert, M. Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-kappaB signaling pathway. *Oncogene*. 2019;38:5873-5889.
I.F.: 7.971
151. Reck, M., Mok, T. S. K., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodriguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., Finley, G., Lee, A., Coleman, S., Deng, Y., Kowanetz, M., Shankar, G., Lin, W., and Socinski, M. A. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. *Lancet Respir Med*. 2019;7:387-401.
I.F.: 25.094
152. Reichert, T., Fakhry, N., Lavieille, J. P., Amodru, V., Sebag, F., Romanet, P., Loundou, A., Castinetti, F., Pacak, K., Montava, M., and Taieb, D. Exploring the link between tumour metabolism and succinate dehydrogenase deficiency: A (18) F-FDOPA PET/CT study in head and neck paragangliomas. *Clin Endocrinol (Oxf)*. 2019;91:879-884.
I.F.: 3.380
153. Revon-Riviere, G., Banavali, S., Heississen, L., Gomez Garcia, W., Abdolkarimi, B., Vaithilingum, M., Li, C. K., Leung, P. C., Malik, P., Pasquier, E., Epelman, S., Chantada, G., and Andre, N. Metronomic Chemotherapy for Children in Low- and Middle-Income Countries: Survey of Current Practices and Opinions of Pediatric Oncologists. *J Glob Oncol*. 2019;5:1-8.

I.F.: 0

154. Rochigneux,P., Nault, J. C., Mallet, F., Chretien, A. S., Barget, N., Garcia, A. J., Del Pozo, L., Bourcier, V., Blaise, L., Grando-Lemaire, V., N'Kontchou, G., Nahon, P., Seror, O., Ziol, M., Ganne-Carrie, N., and Olive, D. Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma. *Oncoimmunology*. 2019;8:1615818

I.F.: 5.869

155. Rodallec,A., Fanciullino, R., Benzekry, S., and Ciccolini, J. Is There Any Room for Pharmacometrics With Immuno-Oncology Drugs? Input from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology. *Anticancer Res*. 2019;39:3419-3422.

I.F.: 1.994

156. Rodrigues,F., Edjlali, M., GeorGIN-Lavialle, S., Chandesris, O., Barete, S., Bouktit, H., Dubreuil, P., Hamidou, M., Saadoun, D., Gaillard, R., and Hermine, O. Neuroinflammatory disorders and mastocytosis: a possible association? *J Allergy Clin Immunol Pract*. 2019;7:2878-2881.e1.

I.F.: 7.574

157. Roger,E., Martel, S., Bertrand-Chapel, A., Depollier, A., ChuvIN, N., Pommier, R. M., Yacoub, K., Caligaris, C., Cardot-Ruffino, V., Chauvet, V., Aires, S., Mohkan, K., Mabrut, J. Y., Adham, M., Fenouil, T., Hervieu, V., Broutier, L., Castets, M., Neuzillet, C., Cassier, P. A., Tomasini, R., Sentis, S., and Bartholin, L. Schwann cells support oncogenic potential of pancreatic cancer cells through TGFbeta signaling. *Cell Death Dis*. 2019;10:886

I.F.: 6.304

158. Rossignol,J., Polivka, L., Maouche-Chretien, L., Frenzel, L., Dubreuil, P., and Hermine, O. Recent advances in the understanding and therapeutic management of mastocytosis. *F1000Res*. 2019;8:1961

I.F.: 0

159. Sabatier,R., Charafe-Jauffret, E., Pierga, J. Y., Cure, H., Lambaudie, E., Genre, D., Houvenaeghel, G., Viens, P., Ginestier, C., Bertucci, F., Sfumato, P., Extra, J. M., and Goncalves, A. Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer. *J Clin Med*. 2019;8:E612

I.F.: 5.688

160. Saez-Ayala,M., Laban Yekwa, E., Mondielli, C., Roux, L., Hernandez, S., Bailly, F., Cotelte, P., Rogolino, D., Canard, B., Ferron, F., and Alvarez, K. Metal chelators for the inhibition of the lymphocytic choriomeningitis virus endonuclease domain. *Antiviral Res*. 2019;162:79-89.

I.F.: 4.101

161. Salaun,P.Y., Abgral, R., Malard, O., Querellou-Lefranc, S., Quere, G., Wartski, M., Coriat, R., Hindie, E., Taieb, D., Tabarin, A., Girard, A., Grellier, J. F., Brenot-Rossi, I., Groheux, D., Rousseau, C., Deandreis, D., Alberini, J. L., Bodet-Milin, C., Itti, E., Casasnovas, O., Kraeber-Bodere, F., Moreau, P., Philip, A., Balleyguier, C., Lucian, A., and Cachin, F. Actualisation des recommandations de bonne pratique clinique pour l'utilisation de la TEP en cancérologie. *Bull Cancer*. 2019;106:262-274.

I.F.: 0.912

162. Santofimia-Castano,P., Rizzuti, B., Xia, Y., Abian, O., Peng, L., Velazquez-Campoy, A., Iovanna, J. L., and Neira, J. L. Designing and repurposing drugs to target intrinsically disordered proteins for cancer treatment: using NUPR1 as a paradigm. *Mol Cell Oncol*. 2019;6:e1612678

I.F.: 0

163. Santofimia-Castano,P., Xia, Y., Lan, W., Zhou, Z., Huang, C., Peng, L., Soubeyran, P., Velazquez-Campoy, A., Abian, O., Rizzuti, B., Neira, J. L., and Iovanna, J. L. Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis. *J Clin Invest*. 2019;129:2500-2513.

I.F.: 11.864

164. Santofimia-Castano,P., Xia, Y., Peng, L., Velazquez-Campoy, A., Abian, O., Lan, W., Lomberk, G., Urrutia, R., Rizzuti, B., Soubeyran, P., Neira, J. L., and Iovanna, J. L. Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma. *Cells*. 2019;8:E1453
I.F.: 4.366
165. Schneider,B.K., Boyer, A., Ciccolini, J., Barlesi, F., Wang, K., Benzekry, S., and Mochel, J. P. Optimal Scheduling of Bevacizumab and Pemetrexed/cisplatin Dosing in Non-Small Cell Lung Cancer. *CPT Pharmacometrics Syst Pharmacol*. 2019;8:577-586.
I.F.: 0
166. Segal-Bendirdjian,E. and Geli, V. Non-canonical Roles of Telomerase: Unraveling the Imbroglgio. *Front Cell Dev Biol*. 2019;7:332
I.F.: 5.201
167. Shiraki,M., Xu, X., Iovanna, J. L., Kukita, T., Hirata, H., Kamohara, A., Kubota, Y., Miyamoto, H., Mawatari, M., and Kukita, A. Deficiency of stress-associated gene Nupr1 increases bone volume by attenuating differentiation of osteoclasts and enhancing differentiation of osteoblasts. *FASEB J*. 2019;33:8836-8852.
I.F.: 4.966
168. Sidorov,P., Naulaerts, S., Arieu-Bonnet, J., Pasquier, E., and Ballester, P. J. Predicting Synergism of Cancer Drug Combinations Using NCI-ALMANAC Data. *Front Chem*. 2019;7:509
I.F.: 3.693
169. Sousa,F., Dhaliwal, H. K., Gattacceca, F., Sarmento, B., and Amiji, M. M. Enhanced anti-angiogenic effects of bevacizumab in glioblastoma treatment upon intranasal administration in polymeric nanoparticles. *J Control Release*. 2019;309:37-47.
I.F.: 7.727
170. Swayden,M., Alzeeb, G., Masoud, R., Berthois, Y., Audebert, S., Camoin, L., Hannouche, L., Vachon, H., Gayet, O., Bigonnet, M., Roques, J., Silvy, F., Carrier, A., Dusetti, N., Iovanna, J. L., and Soubeyran, P. PML hyposumoylation is responsible for the resistance of pancreatic cancer. *FASEB J*. 2019;33:12447-12463.
I.F.: 4.966
171. Swayden,M., Dobric, A., Berthois, Y., Villalba, H., Audebert, S., Camoin, L., Iovanna, J. L., and Soubeyran, P. Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations. *J Vis Exp*. 2019;153:e60402
I.F.: 1.108
172. Swayden,M., Soubeyran, P., and Iovanna, J. L. Upcoming Revolutionary Paths in Preclinical Modeling of Pancreatic Adenocarcinoma. *Front Oncol*. 2019;9:1443
I.F.: 4.848
173. Terciolo,C., Dapoigny, M., and Andre, F. Beneficial effects of *Saccharomyces boulardii* CNCM I-745 on clinical disorders associated with intestinal barrier disruption. *Clin Exp Gastroenterol*. 2019;12:67-82.
I.F.: 0
174. Tomasini,P., Egea, J., Souquet-Bressand, M., Greillier, L., and Barlesi, F. Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases. *Ther Adv Respir Dis*. 2019;13:1-11.
I.F.: 3.286
175. Tomasini,P. and Greillier, L. Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer? *Transl Lung Cancer Res*. 2019;8:S323-S326.
I.F.: 5.132

176. Torres-Gutierrez,E., Perez-Cervera, Y., Camoin, L., Zenteno, E., Aquino-Gil, M. O., Lefebvre, T., Cabrera-Bravo, M., Reynoso-Ducoing, O., Bucio-Torres, M. I., and Salazar-Schettino, P. M. Identification of O-GlcNacetylated Proteins in *Trypanosoma cruzi*. *Front Endocrinol (Lausanne)*. 2019;10:199
I.F.: 3.644
177. Toulmonde,M., Pulido, M., Ray-Coquard, I., Andre, T., Isambert, N., Chevreau, C., Penel, N., Bompas, E., Saada, E., Bertucci, F., Lebbe, C., Le Cesne, A., Soulie, P., Piperno-Neumann, S., Sweet, S., Cecchi, F., Hembrough, T., Bellera, C., Kind, M., Crombe, A., Lucchesi, C., Le Loarer, F., Blay, J. Y., and Italiano, A. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. *Lancet Oncology*. 2019;20:1263-1272.
I.F.: 33.752
178. Tyran,M., Carbuccia, N., Garnier, S., Guille, A., Adelaide, J., Finetti, P., Toulzian, J., Viens, P., Tallet, A., Goncalves, A., Metellus, P., Birnbaum, D., Chaffanet, M., and Bertucci, F. A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases. *Cancers (Basel)*. 2019;11:E665-I.F.: 6.126
179. Tyrkalska,S.D., Perez-Oliva, A. B., Rodriguez-Ruiz, L., Martinez-Morcillo, F. J., Alcaraz-Perez, F., Martinez-Navarro, F. J., Lachaud, C., Ahmed, N., Schroeder, T., Pardo-Sanchez, I., Candel, S., Lopez-Munoz, A., Choudhuri, A., Rossmann, M. P., Zon, L. I., Cayuela, M. L., Garcia-Moreno, D., and Mulero, V. Inflammasome Regulates Hematopoiesis through Cleavage of the Master Erythroid Transcription Factor GATA1. *Immunity*. 2019;51:50-63.e5.
I.F.: 22.553
180. Vacca,P., Pesce, S., Greppi, M., Fulcheri, E., Munari, E., Olive, D., Mingari, M. C., Moretta, A., Moretta, L., and Marcenaro, E. PD-1 is expressed by and regulates human group 3 innate lymphoid cells in human decidua. *Mucosal Immunol*. 2019;12:624-631.
I.F.: 7.352
181. Van Berckelaer,C., Rypens, C., Van Dam, P., Pouillon, L., Parizel, M., Schats, K. A., Kockx, M., Tjalma, W. A. A., Vermeulen, P., Van Laere, S., Bertucci, F., Colpaert, C., and Dirix, L. Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression. *Breast Cancer Res*. 2019;21:28
I.F.: 4.988
182. Varela Cagetti,L., Zemmour, C., Salem, N., Minsat, M., Ferre, M., Mailleux, H., Giovaninni, M., Lelong, B., De Chaisemartin, C., Ries, P., Poizat, F., Tallet, A., and Moureau-Zabotto, L. High-dose-rate vs. low-dose-rate interstitial brachytherapy boost for anal canal cancers. *Brachytherapy*. 2019;18:814-822.
I.F.: 2.030
183. Veal,G.J., Amankwatia, E. B., Paludetto, M. N., Mocklinghoff, T., Thomson, F., Andre, N., Ciccolini, J., and Chatelut, E. Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future Opportunities. *Ther Drug Monit*. 2019;41:142-159.
I.F.: 2.047
184. Venton,G., Turcanu, M., Colle, J., Thuny, F., Chebrek, S., Farnault, L., Mercier, C., Ivanov, V., Fanciullino, R., Suchon, P., Jarrot, P. A., Aissi, K., Roche, P., Cautela, J., Arcani, R., and Costello, R. Pulmonary hypertension in patients with myeloproliferative neoplasms: A large cohort of 183 patients. *Eur J Intern Med*. 2019;68:71-75.
I.F.: 3.660
185. Verweij,F.J., Revenu, C., Arras, G., Dingli, F., Loew, D., Pegtel, D. M., Follain, G., Allio, G., Goetz, J. G., Zimmermann, P., Herbomel, P., Del Bene, F., Raposo, G., and van Niel, G. Live Tracking of Inter-organ Communication by Endogenous Exosomes In Vivo. *Dev Cell*. 2019;48:573-589.
I.F.: 10.092

186. Warnez-Soulie, J., Macia, M., Lac, S., Pecchi, E., Bernard, M., Bendahan, D., Bartoli, M., Carrier, A., and Giannesini, B. Tumor protein 53-induced nuclear protein 1 deficiency alters mouse gastrocnemius muscle function and bioenergetics in vivo. *Physiol Rep.* 2019;7:e14055
I.F.: 0
187. Weisberg, E., Meng, C., Case, A. E., Sattler, M., Tiv, H. L., Gokhale, P. C., Buhrlage, S. J., Liu, X., Yang, J., Wang, J., Gray, N., Stone, R. M., Adamia, S., Dubreuil, P., Letard, S., and Griffin, J. D. Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. *Br J Haematol.* 2019;187:488-501.
I.F.: 5.518
188. Williams, M. M., Mathison, A. J., Christensen, T., Greipp, P. T., Knutson, D. L., Klee, E. W., Zimmermann, M. T., Iovanna, J. L., Lomber, G. A., and Urrutia, R. A. Aurora kinase B-phosphorylated HP1 α functions in chromosomal instability. *Cell Cycle.* 2019;18:1407-1421.
I.F.: 3.699
189. Wojcikowski, M., Siedlecki, P., and Ballester, P. J. Building Machine-Learning Scoring Functions for Structure-Based Prediction of Intermolecular Binding Affinity. *Methods Mol Biol.* 2019;2053:1-12.
I.F.: 0
190. Xerri, L., Adelaide, J., Avenin, M., Guille, A., Taix, S., Bonnet, N., Carbuccia, N., Garnier, S., Mescam, L., Murati, A., Chaffanet, M., Coso, D., Bouabdallah, R., Bertucci, F., and Birnbaum, D. Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome-wide clonal evolution. *Histopathology.* 2019;74:654-662.
I.F.: 3.626
191. Xiao, Y., Ma, D., Zhao, S., Suo, C., Shi, J., Xue, M. Z., Ruan, M., Wang, H., Zhao, J., Li, Q., Wang, P., Shi, L., Yang, W. T., Huang, W., Hu, X., Yu, K., Huang, S., Bertucci, F., Jiang, Y. Z., and Shao, Z. M. Multi-omics profiling reveals distinct microenvironment characterization and suggests immune escape mechanisms of triple-negative breast cancer. *Clin Cancer Res.* 2019;25:5002-5014.
I.F.: 10.107
192. Yamasaki, T., Buric, D., Chacon, C., Audran, G., Braguer, D., Marque, S. R. A., Carre, M., and Bremond, P. Chemical modifications of imidazole-containing alkoxyamines increase C-ON bond homolysis rate: Effects on their cytotoxic properties in glioblastoma cells. *Bioorg Med Chem.* 2019;27:1942-1951.
I.F.: 2.881
193. Zhou, Z., Luo, B., Liu, X., Chen, M., Lan, W., Iovanna, J. L., Peng, L., and Xia, Y. Flavonoid-alkylphospholipid conjugates elicit dual inhibition of cancer cell growth and lipid accumulation. *Chem Commun (Camb).* 2019;55:8919-8922.
I.F.: 5.996
194. Zidi, B., Vincent-Fabert, C., Pouyet, L., Seillier, M., Vandeveld, A., N'Guessan, P., Poplineau, M., Guittard, G., Mancini, S. J. C., Duprez, E., and Carrier, A. TP53INP1 deficiency maintains murine B lymphopoiesis in aged bone marrow through redox-controlled IL-7R/STAT5 signaling. *Proc Natl Acad Sci U S A.* 2019;116:211-216.
I.F.: 9.412

LES PUBLICATIONS DU CRCM – 2020

1. Addi, C., Presle, A., Fremont, S., Cuvelier, F., Rocancourt, M., Milin, F., Schmutz, S., Chamot-Rooke, J., Douche, T., Duchateau, M., Giai Gianetto, Q., Salles, A., Menager, H., Matondo, M., Zimmermann, P., Gupta-Rossi, N., and Echard, A. The Flemmingsome reveals an ESCRT-to-membrane coupling via ALIX/syntenin/syndecan-4 required for completion of cytokinesis. *Nat Commun.* 2020;11:1941
I.F.: 12.121



2. Adelaide, J., Cervera, N., Guille, A., Murati, A., Chaffanet, M., Mozziconacci, M. J., Vey, N., Birnbaum, D., and Gelsi-Boyer, V. Gains of EPOR and ERG genes in adult erythroleukaemia. *Br J Haematol.* 2020;189:e174-e177.
I.F.: 5.518
3. Aguilera, P., Whalen, J., Minguet, C., Churikov, D., Freudenreich, C., Simon, M. N., and Geli, V. The nuclear pore complex prevents sister chromatid recombination during replicative senescence. *Nat Commun.* 2020;11:160
I.F.: 12.121
4. Ahmad, R., Lahuna, O., Sidibe, A., Daulat, A., Zhang, Q., Luka, M., Guillaume, J. L., Gallet, S., Guillonnet, F., Hamroune, J., Polo, S., Prevot, V., Delagrangé, P., Dam, J., and Jockers, R. GPR50-Ctail cleavage and nuclear translocation: a new signal transduction mode for G protein-coupled receptors. *Cell Mol Life Sci.* 2020;77:5189-5205.
I.F.: 6.496
5. Ahmad, S., Ballester, P. J., and Fernandez, M. Editorial: Intelligent Systems for Genome Functional Annotations. *Front Genet.* 2020;11:915
I.F.: 3.260
6. Amatore, F., Ortonne, N., Lopez, M., Orlanducci, F., Castellano, R., Ingen-Housz-Oro, S., De Croos, A., Salvado, C., Gorvel, L., Goubard, A., Collette, Y., Bouabdallah, R., Schiano, J. M., Bonnet, N., Grob, J. J., Gaulard, P., Bagot, M., Bensussan, A., Berbis, P., and Olive, D. ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells. *Blood Adv.* 2020;4:5203-5214.
I.F.: 4.910
7. Amatore, F., Gorvel, L., and Olive, D. Role of Inducible Co-Stimulator (ICOS) in cancer immunotherapy. *Expert Opin Biol Ther.* 2020;20:141-150.
I.F.: 3.224
8. Amiano, N. O., Morelli, M. P., Pellegrini, J. M., Tateosian, N. L., Rolandelli, A., Seery, V., Castello, F. A., Gallego, C., Armitano, R., Stupka, J., Erschen, M. A., Ciallella, L. M., de Casado, G. C., Cusmano, L., Palmero, D. J., Iovanna, J. L., and Garcia, V. E. IFN-gamma and IgG responses to Mycobacterium tuberculosis latency antigen Rv2626c differentiate remote from recent tuberculosis infection. *Sci Rep.* 2020;10:7472
I.F.: 3.998
9. Andre, N., Orbach, D., and Pasquier, E. Metronomic Maintenance for High-Risk Pediatric Malignancies: One Size Will Not Fit All. *Trends Cancer.* 2020;6:819-828.
I.F.: 11.093
10. Ariey-Bonnet, J., Carrasco, K., Le Grand, M., Hoffer, L., Betzi, S., Feracci, M., Tsvetkov, P., Devred, F., Collette, Y., Morelli, X., Ballester, P., and Pasquier, E. In silico molecular target prediction unveils Mebendazole as a potent MAPK14 inhibitor. *Mol Oncol.* 2020;14:3083-3099.
I.F.: 6.574
11. Aulas, A., Finetti, P., Lyons, S. M., Bertucci, F., Birnbaum, D., Acquaviva, C., and Mamessier, E. Revisiting the Concept of Stress in the Prognosis of Solid Tumors: A Role for Stress Granules Proteins? *Cancers (Basel).* 2020;12:E2470
I.F.: 6.126
12. Ba, H. L., Mbatchi, L., Gattacceca, F., Evrard, A., Lacarelle, B., Blanchet, B., Ciccolini, J., and Salas, S. Pharmacogenetics and pharmacokinetics modeling of unexpected and extremely severe toxicities after sorafenib intake. *Pharmacogenomics.* 2020;21:173-179.
I.F.: 2.339
13. Bae, H. J., Dubarry, M., Jeon, J., Soares, L. M., Dargemont, C., Kim, J., Geli, V., and Buratowski, S. The Set1 N-terminal domain and Swd2 interact with RNA polymerase II CTD to recruit COMPASS. *Nat Commun.* 2020;11:2181
I.F.: 12.121



14. Bailly,A.L., Grenier, J. M. P., Cartier-Michaud, A., Bardin, F., Balzano, M., Goubard, A., Lissitzky, J. C., De Grandis, M., Mancini, S. J. C., Serge, A., and Aurrand-Lions, M. GRASP55 Is Dispensable for Normal Hematopoiesis but Necessary for Myc-Dependent Leukemic Growth. *J Immunol.* 2020;204:2685-2696.
I.F.: 4.886
15. Bailly,C., Verschuur, A., Bosdure, E., Dabadie, A., Petit, P., Maues de Paula, A., Coulomb-L'hermine, A., Longy, M., and Andre, N. Pulmonary giant chondromatous hamartoma with multifocal evolution in an infant. *Pediatr Blood Cancer.* 2020;67:e27973
I.F.: 2.355
16. Barlesi,F. and Tomasini, P. Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors. *Lancet Oncology.* 2020;21:607-608.
I.F.: 33.752
17. Barlesi,F., Dixmier, A., Debieuvre, D., Raspaud, C., Auliac, J. B., Benoit, N., Bombaron, P., Moro-Sibilot, D., Audigier-Valette, C., Asselain, B., Egenod, T., Rabeau, A., Fayette, J., Sanchez, M. L., Labourey, J. L., Westeel, V., Lamoureux, P., Cotte, F. E., Allan, V., Daumont, M., Dumanoir, J., Reynaud, D., Calvet, C. Y., Ozan, N., and Perol, M. Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study. *Oncoimmunology.* 2020;9:1744898
I.F.: 5.869
18. Barroso-Gonzalez,J., Garcia-Exposito, L., Hoang, S. M., Lynskey, M. L., Roncaioli, J. L., Ghosh, A., Wallace, C. T., de Vitis, M., Modesti, M., Bernstein, K. A., Sarkar, S. N., Watkins, S. C., and O'Sullivan, R. J. RAD51AP1 Is an Essential Mediator of Alternative Lengthening of Telomeres - Erratum. *Mol Cell.* 2020;79:359
I.F.: 15.584
19. Barthez,M., Poplineau, M., Elrefaey, M., Caruso, N., Graba, Y., and Saurin, A. J. Human ZKSCAN3 and Drosophila M1BP are functionally homologous transcription factors in autophagy regulation. *Sci Rep.* 2020;10:9653
I.F.: 3.998
20. Bennouna,J., Girard, N., Audigier-Valette, C., Le Thuaut, A., Gervais, R., Masson, P., Marcq, M., Molinier, O., Cortot, A., Debieuvre, D., Cadranet, J., Lena, H., Moro-Sibilot, D., Chouaid, C., Mennequier, B., Urban, T., Sagan, C., Perrier, L., Barlesi, F., and Denis, M. G. Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial. *Clin Lung Cancer.* 2020;21:e10-e14.
I.F.: 3.550
21. Berges,R., Tchoghandjian, A., Serge, A., Honore, S., Figarella-Branger, D., Bachmann, F., Lane, H. A., and Braguer, D. EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis. *Oncotarget.* 2020;11:759-774.
I.F.: 0
22. Bernard,P.L., Laletin, V., Pastor, S., Nunes, J. A., and Guittard, G. Une piste en immunothérapie du cancer. Cibler la signalisation des cellules NK. *Med Sci (Paris).* 2020;36:50-55.
I.F.: 0.692
23. Berthezene,J., Reyes, C., Li, T., Coulon, S., Bernard, P., Gachet, Y., and Tournier, S. Aurora B and Condensin are dispensable for chromosome arm and telomere separation during meiosis II. *Mol Biol Cell.* 2020;31:889-905.
I.F.: 3.791
24. Berti,M., Teloni, F., Mijic, S., Ursich, S., Fuchs, J., Palumbieri, M. D., Krietsch, J., Schmid, J. A., Garcin, E. B., Gon, S., Modesti, M., Altmeyer, M., and Lopes, M. Sequential role of RAD51 paralog complexes in replication fork remodeling and restart. *Nat Commun.* 2020;11:3531
I.F.: 12.121

25. Bertucci, A., Bertucci, F., Zemmour, C., Lerebours, F., Pierga, J. Y., Levy, C., Dalenc, F., Grenier, J., Petit, T., Berline, M., and Goncalves, A. PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer. *Front Oncol.* 2020;10:575978
I.F.: 4.848
26. Bertucci, F., Van Laere, S., and Birnbaum, D. Genomic landscape of inflammatory breast cancer identifies potential actionable genetic alterations. *Oncoscience.* 2020;7:57-59.
I.F.: 0
27. Bertucci, F., Finetti, P., Goncalves, A., and Birnbaum, D. The therapeutic response of ER+/HER2 breast cancers differs according to the molecular Basal or Luminal subtype. *NPJ Breast Cancer.* 2020;6:8
I.F.: 6.000
28. Bertucci, F., Rypens, C., Finetti, P., Guille, A., Adelaide, J., Monneur, A., Carbuccia, N., Garnier, S., Dirix, P., Goncalves, A., Vermeulen, P., Debeb, B. G., Wang, X., Dirix, L., Ueno, N. T., Viens, P., Cristofanilli, M., Chaffanet, M., Birnbaum, D., and Van Laere, S. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers. *Mol Oncol.* 2020;14:504-519.
I.F.: 6.574
29. Bertucci, F., Le Corroller-Soriano, A. G., Monneur, A., Fluzin, S., Viens, P., Maraninchi, D., and Goncalves, A. Santé numérique et « cancer hors les murs », Big Data et intelligence artificielle. *Bull Cancer.* 2020;107:102-112.
I.F.: 0.912
30. Bintz, J., Abuelafia, A. M., Gerbe, F., Baudoin, E., Auphan-Anezin, N., Sidot, E., Jay, P., and Iovanna, J. L. Expression of POU2F3 Transcription Factor Control Inflammation, Immunological Recruitment and Metastasis of Pancreatic Cancer in Mice. *Biology (Basel).* 2020;9:E341
I.F.: 3.796
31. Birnbaum, D. J., Finetti, P., Birnbaum, D., and Bertucci, F. Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer-Letter. *Clin Cancer Res.* 2020;26:5539
I.F.: 10.107
32. Bosc, C., Broin, N., Fanjul, M., Saland, E., Farge, T., Courdy, C., Batut, A., Masoud, R., Larrue, C., Skuli, S., Espagnol, N., Pages, J. C., Carrier, A., Bost, F., Bertrand-Michel, J., Tamburini, J., Recher, C., Bertoli, S., Mansat-De Mas, V., Manenti, S., Sarry, J. E., and Joffre, C. Autophagy regulates fatty acid availability for oxidative phosphorylation through mitochondria-endoplasmic reticulum contact sites. *Nat Commun.* 2020;11:4056
I.F.: 12.121
33. Bosc, N., Muller, C., Hoffer, L., Lagorce, D., Bourg, S., Derviaux, C., Gourdel, M. E., Rain, J. C., Miller, T. W., Villoutreix, B. O., Miteva, M. A., Bonnet, P., Morelli, X., Sperandio, O., and Roche, P. Fr-PPiChem: An academic compound library dedicated to protein-protein interactions. *ACS Chem Biol.* 2020;15:1566-1574.
I.F.: 4.434
34. Boucherit, N., Gorvel, L., and Olive, D. 3D Tumor Models and Their Use for the Testing of Immunotherapies. *Front Immunol.* 2020;11:603640
I.F.: 5.085
35. Brandone, N., Mascaux, C., Caselles, K., Rouquette, I., Lantuejoul, S., and Garcia, S. Validation of the QR1 Antibody for the Evaluation of PD-L1 Expression in Non-Small Cell Lung Adenocarcinomas. *Appl Immunohistochem Mol Morphol.* 2020;28:23-29.
I.F.: 1.773
36. Calabro, L., Peters, S., Soria, J. C., Di Giacomo, A. M., Barlesi, F., Covre, A., Altomonte, M., Vegni, V., Gridelli, C., Reck, M., Rizvi, N., and Maio, M. Challenges in lung cancer therapy during the COVID-19 pandemic. *Lancet Respir Med.* 2020;8:542-544.

I.F.: 25.094

37. Carre,T., Thiery, J., Janji, B., Terry, S., Gros, G., Meurice, G., Kieda, C., Olive, D., and Chouaib, S. Selection of tumor-resistant variants following sustained natural killer cell-mediated immune stress. *Oncol Rep.* 2020;45:582-594.

I.F.: 3.417

38. Carrier,A. Actualités sur le lien métabolisme et cancers, l'essentiel du Congrès international Métabolisme et Cancer 2019. *Bull Cancer.* 2020;107:281-282.

I.F.: 0.912

39. Cervera,N., Lhoumeau, A. C., Adelaide, J., Guille, A., Murati, A., Mozziconacci, M. J., Vey, N., Birnbaum, D., and Gelsi-Boyer, V. Acute erythroid leukemias have a distinct molecular hierarchy from non-erythroid acute myeloid leukemias. *Haematologica.* 2020;105:e340-e342.

I.F.: 7.116

40. Chames,P. and Rothbauer, U. Special Issue: Nanobody. *Antibodies (Basel).* 2020;9:E6

I.F.: 0

41. Chan Kwong,A.H.P., Calvier, E. A. M., Fabre, D., Gattacceca, F., and Khier, S. Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine. *J Pharmacokinet Pharmacodyn.* 2020;47:431-446.

I.F.: 2.461

42. Chansel-Da Cruz,M., Hohl, M., Ceppi, I., Kermasson, L., Maggiorella, L., Modesti, M., de Villartay, J. P., Ileri, T., Cejka, P., Petrini, J. H. J., and Revy, P. A Disease-Causing Single Amino Acid Deletion in the Coiled-Coil Domain of RAD50 Impairs MRE11 Complex Functions in Yeast and Humans. *Cell Rep.* 2020;33:108559

I.F.: 8.109

43. Charafe-Jauffret,E. Nouvelles avancées sur les cellules souches du cancer. L'essentiel du Congrès Sunrise 2019. *Bull Cancer.* 2020;107:140-141.

I.F.: 0.912

44. Chenesseau,J., Bourlard, D., Cluzel, A., Trousse, D., D'Journo, X. B., and Thomas, P. A. Intent-to-cure surgery for small-cell lung cancer in the era of contemporary screening and staging methods. *Interact Cardiovasc Thorac Surg.* 2020;30:541-545.

I.F.: 1.675

45. Ciccolini,J., Benzekry, S., and Barlesi, F. Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC. *Br J Cancer.* 2020;123:337-338.

I.F.: 5.791

46. Cifaldi,L., Di, S. J., and Olive, D. Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of Cancer. *Front Immunol.* 2020;11:1132

I.F.: 5.085

47. Coiffard,B., Reynaud-Gaubert, M., Rey, J. B., Cousin, E., Grosdidier, C., Nicolino-Brunet, C., Dignat-George, F., Papazian, L., Thomas, P. A., Barbolosi, D., and Serre, R. Mathematical modeling of peripheral blood neutrophil kinetics to predict CLAD after lung transplantation. *Transpl Immunol.* 2020;62:101321

I.F.: 1.624

48. Collignon,A., Hospital, M. A., Montersino, C., Courtier, F., Charbonnier, A., Saillard, C., D'incan, E., Mohty, B., Guille, A., Adelaide, J., Carbuccia, N., Garnier, S., Mozziconacci, M. J., Zemmour, C., Pakradouni, J., Restouin, A., Castellano, R., Chaffanet, M., Birnbaum, D., Collette, Y., and Vey, N. A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study. *Blood Cancer J.* 2020;10:64

I.F.: 8.023



49. Couderc, A.L., Tomasini, P., Nouguerede, E., Rey, D., Correard, F., Montegut, C., Thomas, P. A., Villani, P., Barlesi, F., and Greillier, L. Older Patients Treated for Lung and Thoracic Cancers: Unplanned Hospitalizations and Overall Survival. *Clin Lung Cancer*. 2020
I.F.: 3.550
50. Coulon, S. and Vaurs, M. Telomeric transcription and telomere rearrangements in quiescent cells. *J Mol Biol*. 2020;432:4220-4231.
I.F.: 4.760
51. Courtier, F., Garnier, S., Carbuccia, N., Guille, A., Adelaide, J., Chaffanet, M., Hirsch, P., Luque Paz, D., Slama, B., Vey, N., Ugo, V., Delhommeau, F., Rey, J., Birnbaum, D., and Murati, A. Targeted molecular characterization shows differences between primary and secondary myelofibrosis. *Genes Chromosomes Cancer*. 2020;59:30-39.
I.F.: 3.444
52. Crane, G., Smoljanovic, V., Khan, N., Gally, S., Tomasini, P., Lara, N., Gondos, A., and Hammerschmidt, S. Application of clinical trial inclusion criteria to clinical practice patients to quantify the burden of CNS metastases on health-related quality of life and healthcare resource use in patients with NSCLC. *Lung Cancer*. 2020;149:144-153.
I.F.: 4.702
53. Dadone-Montaudie, B., Laroche-Clary, A., Mongis, A., Chamorey, E., Mauro, I. D., Chaire, V., Finetti, P., Schiappa, R., Le Loarer, F., Birtwisle-Peyrottes, I., Michiels, J. F., Bertucci, F., Pedeutour, F., Italiano, A., and Bianchini, L. Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting. *Cancers (Basel)*. 2020;12:E3058
I.F.: 6.126
54. David, G. and Zimmermann, P. Heparanase Involvement in Exosome Formation. *Adv Exp Med Biol*. 2020;1221:285-307.
I.F.: 2.450
55. Debnath, S.B.C., Fauquet, C., Tallet, A., Goncalves, A., Lavandier, S., Jandard, F., Tonneau, D., and Darreon, J. High spatial resolution inorganic scintillator detector for high energy X-ray beam at small field irradiation. *Med Phys*. 2020;47:1364-1371.
I.F.: 3.317
56. Delahaye, M.C., Salem, K. I., Pelletier, J., Aurrand-Lions, M., and Mancini, S. J. C. Toward Therapeutic Targeting of Bone Marrow Leukemic Niche Protective Signals in B-Cell Acute Lymphoblastic Leukemia. *Front Oncol*. 2020;10:606540
I.F.: 4.848
57. Delamarre, A., Barthe, A., de La Roche Saint-Andre, C., Luciano, P., Forey, R., Padioleau, I., Skrzypczak, M., Ginalski, K., Geli, V., Pasero, P., and Lengronne, A. MRX Increases Chromatin Accessibility at Stalled Replication Forks to Promote Nascent DNA Resection and Cohesin Loading. *Mol Cell*. 2020;77:395-410.e3.
I.F.: 15.584
58. Delconte, R.B., Guittard, G., Goh, W., Hediye-Zadeh, S., Hennessy, R. J., Rautela, J., Davis, M. J., Souza-Fonseca-Guimaraes, F., Nunes, J. A., and Huntington, N. D. NK Cell Priming From Endogenous Homeostatic Signals Is Modulated by CIS. *Front Immunol*. 2020;11:75
I.F.: 5.085
59. Devillier, R., Chretien, A. S., Pagliardini, T., Salem, N., Blaise, D., and Olive, D. Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy. *J Leukoc Biol*. 2020
I.F.: 3.757
60. Diaz-Garcia, C., Hornos, F., Giudici, A. M., Camara-Artigas, A., Luque-Ortega, J. R., Arbe, A., Rizzuti, B., Alfonso, C., Forwood, J. K., Iovanna, J. L., Gomez, J., Prieto, M., Coutinho, A., and Neira, J. L. Human importin alpha3 and its N-terminal truncated form, without the importin-beta-binding domain, are oligomeric species with a low conformational stability in solution. *Biochim Biophys Acta Gen Subj*. 2020;1864:129609
I.F.: 3.422

61. Ding, L., Lyu, Z., Louis, B., Tintaru, A., Laurini, E., Marson, D., Zhang, M., Shao, W., Jiang, Y., Bouhlef, A., Balasse, L., Garrigue, P., Mas, E., Giorgio, S., Iovanna, J. L., Huang, Y., Pricl, S., Guillet, B., and Peng, L. Surface Charge of Supramolecular Nanosystems for In Vivo Biodistribution: A MicroSPECT/CT Imaging Study. *Small*. 2020;e2003290
I.F.: 11.459
62. Doghman-Bouguerra, M., Finetti, P., Durand, N., Parise, I. Z. S., Sbiera, S., Cantini, G., Canu, L., Hescot, S., Figueiredo, M. M. O., Komechen, H., Sbiera, I., Nesi, G., Paci, A., Al Ghuzlan, A., Birnbaum, D., Baudin, E., Luconi, M., Fassnacht, M., Figueiredo, B. C., Bertucci, F., and Lalli, E. Cancer-testis Antigen FATE1 Expression in Adrenocortical Tumors Is Associated with A Pervasive Autoimmune Response and Is A Marker of Malignancy in Adult, but Not Children, *ACC. Cancers (Basel)*. 2020;12:E689
I.F.: 6.126
63. Domblides, C., Leroy, K., Monnet, I., Mazieres, J., Barlesi, F., Gounant, V., Baldacci, S., Mennecier, B., Toffart, A. C., Audigier-Valette, C., Doucet, L., Giroux-Leprieur, E., Guisier, F., Ricordel, C., Molinier, O., Perol, M., Pichon, E., Robinet, G., Templement-Grangerat, D., Ruppert, A. M., Rabbe, N., Antoine, M., and Wislez, M. Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma. *J Thorac Oncol*. 2020;15:860-866.
I.F.: 13.357
64. Dong, Y., Chen, Y., Zhu, D., Shi, K., Ma, C., Zhang, W., Rocchi, P., Jiang, L., and Liu, X. Self-assembly of amphiphilic phospholipid peptide dendrimer-based nanovectors for effective delivery of siRNA therapeutics in prostate cancer therapy. *J Control Release*. 2020;322:425
I.F.: 7.727
65. Doyen, J., Sunyach, M. P., Almairac, F., Bourg, V., Naghavi, A. O., Duhil de Benaze, A., Claren, A., Padovani, L., Benezery, K., Noel, G., Hannoun-Levi, J. M., Guedea, F., Giralt, J., Vidal, M., Baudin, G., Opitz, L., Claude, L., and Bondiau, P. Y. Early Toxicities After High Dose Rate Proton Therapy in Cancer Treatments. *Front Oncol*. 2020;10:613089
I.F.: 4.848
66. Drilon, A., Siena, S., Dziadziuszko, R., Barlesi, F., Krebs, M. G., Shaw, A. T., de Braud, F., Rolfo, C., Ahn, M. J., Wolf, J., Seto, T., Cho, B. C., Patel, M. R., Chiu, C. H., John, T., Goto, K., Karapetis, C. S., Arkenau, H. T., Kim, S. W., Ohe, Y., Li, Y. C., Chae, Y. K., Chung, C. H., Otterson, G. A., Murakami, H., Lin, C. C., Tan, D. S. W., Prenen, H., Riehl, T., Chow-Maneval, E., Simmons, B., Cui, N., Johnson, A., Eng, S., Wilson, T. R., and Doebele, R. C. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. *Lancet Oncology*. 2020;21:261-270.
I.F.: 33.752
67. Dufour, C., Foulon, S., Geoffray, A., Masliah-Planchon, J., Figarella-Branger, D., Guerrini-Rousseau, L., Faure-Contier, C., Icher, C., Bertozzi, A. I., Leblond, P., Akbaraly, T., Bourdeaut, F., Andre, N., Chappe, C., Schneider, P., De Carli, E., Chastagner, P., Berger, C., Lejeune, J., Soler, C., Entz-Werle, N., and Delisle, M. B. Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase 2 trial PNET HR+5. *Neuro Oncol*. 2020
I.F.: 10.247
68. Dusetti, N. and Iovanna, J. L. Organoides dérivés des adénocarcinomes pancréatiques. *Med Sci (Paris)*. 2020;36:57-62.
I.F.: 0.692
69. Egea-Jimenez, A. L. and Zimmermann, P. Lipids in Exosome Biology. *Handb Exp Pharmacol*. 2020;259:309-336.
I.F.: 0
70. El Kababri, M., Benmiloud, S., Cherkaoui, S., El Houdzi, J., Maani, K., Ansari, N., Khoubila, N., Kili, A., El Khorassani, M., Madani, A., Tazi, M. A., Ahid, S., Hessissen, L., Quessar, A., Harif, M., Khattab, M., and Andre, N. Metro-SMHOP 01: Metronomics combination with cyclophosphamide-etoposide and valproic acid for refractory and relapsing pediatric malignancies. *Pediatr Blood Cancer*. 2020;67:e28508
I.F.: 2.355
71. Fagnan, A., Bagger, F. O., Pique-Borras, M. R., Ignacimoutou, C., Caulier, A., Lopez, C., Robert, E., Uzan, B., Gelsi-Boyer, V., Aid, Z., Thirant, C., Moll, U., Tauchmann, S., Kurtovic-Kozaric, A., Maciejewski, J. P., Dierks, C., Spinelli, O., Salmoiraghi, S.,

- Pabst, T., Shimoda, K., Deleuze, V., Lapillonne, H., Sweeney, C., Mansat-De Mas, V., Leite, B., Kadri, Z., Malinge, S., de Botton, S., Micol, J. B., Kile, B. T., Carmichael, C. L., Iacobucci, I., Mullighan, C. G., Carroll, M. P., Valent, P., Bernard, O. A., Delabesse, E., Vyas, P., Birnbaum, D., Anguita, E., Garçon, L., Soler, E., Schwaller, J., and Mercher, T. Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. *Blood*. 2020;136:698-714.
I.F.: 17.794
72. Fanciullino, R., Ciccolini, J., and Milano, G. COVID-19 vaccine race: watch your step for cancer patients. *Br J Cancer*. 2020;124:860-861.
I.F.: 5.791
73. Ferrer, F., Solas, C., Giocanti, M., Lacarelle, B., Deville, J. L., Gravis, G., and Ciccolini, J. A simple and rapid liquid chromatography-mass spectrometry method to assay cabozantinib in plasma: Application to therapeutic drug monitoring in patients with renal cell carcinoma. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2020;1138:121968
I.F.: 3.004
74. Ferrer, F., Fanciullino, R., Milano, G., and Ciccolini, J. Towards rational cancer therapeutics: optimizing dosing, delivery, scheduling and combinations. *Clin Pharmacol Ther*. 2020;103:458-470.
I.F.: 6.565
75. Fourdrain, A., Bouabdallah, I., Gust, L., Cassir, N., Brioude, G., Falcoz, P. E., Alifano, M., Le Rochais, J. P., D'Annoville, T., Trousse, D., Loundou, A., Leone, M., Papazian, L., Thomas, P. A., and D'Journo, X. B. Screening and topical decolonization of preoperative nasal *Staphylococcus aureus* carriers to reduce the incidence of postoperative infections after lung cancer surgery: a propensity matched study. *Interact Cardiovasc Thorac Surg*. 2020;30:552-558.
I.F.: 1.675
76. Fraunhoffer, N. A., Meilerman, A., Bigonnet, M., Gayet, O., Roque, J., Telle, E., Santofimia-Castano, P., Borrello, M. T., Chuluyan, E., Dusetti, N., and Iovanna, J. L. Evidencing a pancreatic ductal adenocarcinoma subpopulation sensitive to the proteasome inhibitor Carfilzomib. *Clin Cancer Res*. 2020;26:5506-5519.
I.F.: 10.107
77. Fresnais, L. and Ballester, P. J. The impact of compound library size on the performance of scoring functions for structure-based virtual screening. *Brief Bioinform*. 2020
I.F.: 8.990
78. Ganier, L., Morelli, X., and Borg, J. P. Rôle en cancérologie et ciblage du récepteur à activité tyrosine kinase PTK7. *Med Sci (Paris)*. 2020;36:42-46.
I.F.: 0.692
79. Garassino, M. C., Whisenant, J. G., Huang, L. C., Trama, A., Torri, V., Agustoni, F., Baena, J., Banna, G., Berardi, R., Bettini, A. C., Bria, E., Brighenti, M., Cadranel, J., De Toma, A., Chini, C., Cortellini, A., Felip, E., Finocchiaro, G., Garrido, P., Genova, C., Giusti, R., Gregorc, V., Grossi, F., Grosso, F., Intagliata, S., La Verde, N., Liu, S. V., Mazieres, J., Mercadante, E., Michielin, O., Minuti, G., Moro-Sibilot, D., Pasello, G., Passaro, A., Scotti, V., Solli, P., Stroppa, E., Tiseo, M., Viscardi, G., Voltolini, L., Wu, Y. L., Zai, S., Pancaldi, V., Dingemans, A. M., Van Meerbeeck, J., Barlesi, F., Wakelee, H., Peters, S., and Horn, L. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. *Lancet Oncology*. 2020;21:914-922.
I.F.: 33.752
80. Ghislat, G., Rahman, T., and Ballester, P. J. Identification and Validation of Carbonic Anhydrase II as the First Target of the Anti-Inflammatory Drug Actarit. *Biomolecules*. 2020;10:E1570
I.F.: 4.082
81. Ghossoub, R., Chery, M., Audebert, S., Leblanc, R., Egea-Jimenez, A. L., Lembo, F., Mammar, S., Le Dez, F., Camoin, L., Borg, J. P., Rubinstein, E., David, G., and Zimmermann, P. Tetraspanin-6 negatively regulates exosome production. *Proc Natl Acad Sci U S A*. 2020;117:5913-5922.
I.F.: 9.412

82. Girard,C.A., Lecacheur, M., Ben Jouira, R., Berestjuk, I., Diazi, S., Prod'Homme, V., Mallavialle, A., Larbret, F., Gesson, M., Schaub, S., Pisano, S., Audebert, S., Mari, B., Gaggioli, C., Leucci, E., Marine, J. C., Deckert, M., and Tartare-Deckert, S. A feed-forward mechanosignaling loop confers resistance to therapies targeting the MAPK pathway in BRAF-mutant melanoma. *Cancer Res.* 2020;80:1927-1941.
I.F.: 9.727
83. Girard,N., Greillier, L., Zalcmán, G., Cadranel, J., Moro-Sibilot, D., Mazieres, J., Audigier-Valette, C., Bennouna, J., Besse, B., Cortot, A., Couraud, S., Duruisseaux, M., Giroux-Leprieur, E., Toffart, A. C., Westeel, V., and Wislez, M. Proposals for managing patients with thoracic malignancies during COVID-19 pandemic. *Respir Med Res.* 2020;78:100769
I.F.: 0
84. Giroux,P., Bhajun, R., Segard, S., Picquenot, C., Charavay, C., Desquilles, L., Pinna, G., Ginestier, C., Denis, J., Cherradi, N., and Guyon, L. miRViz: a novel webserver application to visualize and interpret microRNA datasets. *Nucleic Acids Res.* 2020;48:W252-W261.
I.F.: 11.502
85. Gobbin,E., Toffart, A. C., Perol, M., Assie, J. B., Duruisseaux, M., Coupez, D., Dubos, C., Westeel, V., Delaunay, M., Guisier, F., Veillon, R., Gounant, V., Leprieur, E. G., Vanel, F. R., Chaabane, N., Dansin, E., Babey, H., Decroisette, C., Barlesi, F., Daniel, C., Fournel, P., Mezquita, L., Oulkhair, Y., Canellas, A., Duchemann, B., Molinier, O., Alcazer, V., Moro-Sibilot, D., and Levra, M. G. Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients. *Clin Lung Cancer.* 2020;21:e497-e510.
I.F.: 3.550
86. Goldman,J.W., Mazieres, J., Barlesi, F., Dragnev, K. H., Koczywas, M., Goskel, T., Cortot, A. B., Girard, N., Wessler, C., Bischoff, H., Nadal, E., Park, K., Lu, S., Taus, A., Cobo, M., Estrem, S. T., Wijayawardana, S. R., Turner, K., Oakley, G. J., III, Hurt, K. C., Chiang, A. Y., Hossain, A. M., John, W. J., and Paz-Ares, L. A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER. *Front Oncol.* 2020;10:578756
I.F.: 4.848
87. Goncalves,A., Mezni, E., and Bertucci, F. Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results. *Curr Opin Oncol.* 2020;32:585-593.
I.F.: 3.336
88. Goncalves,A., Bertucci, A., and Bertucci, F. PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond? *Cancers (Basel).* 2020;12:E1378
I.F.: 6.126
89. Gonzalez,A., Estaras, M., Martinez-Morcillo, S., Martinez, R., Garcia, A., Estevez, M., Santofimia-Castano, P., Tapia, J. A., Moreno, N., Perez-Lopez, M., Miguez, M. P., Blanco-Fernandez, G., Lopez-Guerra, D., Fernandez-Bermejo, M., Mateos, J. M., Vara, D., Roncero, V., and Salido, G. M. Melatonin modulates red-ox state and decreases viability of rat pancreatic stellate cells. *Sci Rep.* 2020;10:6352-I.F.: 3.998
90. Gorvel,L. and Olive, D. Targeting the "PVR-TIGIT axis" with immune checkpoint therapies. *F1000Res.* 2020;9:354
I.F.: 0
91. Guegan,J.P., Ginestier, C., Charafe-Jauffret, E., Ducret, T., Quignard, J. F., Vacher, P., and Legembre, P. CD95/Fas and metastatic disease: What does not kill you makes you stronger. *Semin Cancer Biol.* 2020;60:121-131.
I.F.: 11.090
92. Hartung,F., Kruwel, T., Shi, X., Pfizenmaier, K., Kontermann, R., Chames, P., Alves, F., and Pardo, L. A. A Novel Anti-Kv10.1 Nanobody Fused to Single-Chain TRAIL Enhances Apoptosis Induction in Cancer Cells. *Front Pharmacol.* 2020;11:686
I.F.: 4.225

93. Heeke,S., Benzaquen, J., Hofman, V., Ilie, M., Allegra, M., Long-Mira, E., Lassalle, S., Tanga, V., Salacroup, C., Bonnetaud, C., Fayada, J., Gazoppi, L., Ribeyre, L., Castelnau, O., Garnier, G., Cattet, F., Nanni, I., de Fraipont, F., Cohen, C., Berthet, J. P., Leroy, S., Poudenx, M., Marquette, C. H., Denis, M. G., Barlesi, F., and Hofman, P. Critical Assessment in Routine Clinical Practice of Liquid Biopsy for EGFR Status Testing in Non-Small-Cell Lung Cancer: A Single-Laboratory Experience (LPCE, Nice, France). *Clin Lung Cancer*. 2020;21:56-65.e8.
I.F.: 3.550
94. Hofman,P., Rouleau, E., Sabourin, J. C., Denis, M., Deleuze, J. F., Barlesi, F., and Laurent-Puig, P. Predictive molecular pathology in non-small cell lung cancer in France: The past, the present and the perspectives. *Cancer Cytopathol*. 2020;128:601-610.
I.F.: 3.703
95. Hofman,V., Benzaquen, J., Heeke, S., Lassalle, S., Poudenx, M., Long, E., Lanteri, E., Bordone, O., Lespinet, V., Tanga, V., Bonnetaud, C., Bille, Y., Ilie, M., Marquette, C., Barlesi, F., Boutros, J., and Hofman, P. Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry: A single laboratory experience (LPCE, Nice, France). *Lung Cancer*. 2020;145:58-62.
I.F.: 4.702
96. Hong,D.S., Fakhri, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., Bang, Y. J., Dy, G. K., Krauss, J. C., Kuboki, Y., Kuo, J. C., Coveler, A. L., Park, K., Kim, T. W., Barlesi, F., Munster, P. N., Ramalingam, S. S., Burns, T. F., Meric-Bernstam, F., Hearn, H., Ngang, J., Ngarmchamnanrith, G., Kim, J., Houk, B. E., Canon, J., Lipford, J. R., Friberg, G., Lito, P., Govindan, R., and Li, B. T. KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors. *N Engl J Med*. 2020;383:1207-1217.
I.F.: 74.699
97. Honselmann,K.C., Finetti, P., Birnbaum, D. J., Monsalve, C. S., Wellner, U. F., Begg, S. K. S., Nakagawa, A., Hank, T., Li, A., Goldsworthy, M. A., Sharma, H., Bertucci, F., Birnbaum, D., Tai, E., Ligorio, M., Ting, D. T., Schilling, O., Biniossek, M. L., Bronsert, P., Ferrone, C. R., Keck, T., Mino-Kenudson, M., Lillemoe, K. D., Warshaw, A. L., Fernandez-Del Castillo, C., and Liss, A. S. Neoplastic-stromal cell crosstalk regulates matrix expression in pancreatic cancer. *Mol Cancer Res*. 2020;18:1889-1902.
I.F.: 4.630
98. Hua,G., Bergon, A., Cauchy, P., Kahn-Perles, B., Bertucci, F., Birnbaum, D., Benkirane-Jessel, N., and Imbert, J. ERBB2b mRNA isoform encodes a nuclear variant of the ERBB2 oncogene in breast cancer. *J Cell Biochem*. 2020;121:4870-4886.
I.F.: 4.237
99. Imbert,C. and Olive, D. Gamma delta T Cells in Tumor Microenvironment. *Adv Exp Med Biol*. 2020;1273:91-104.
I.F.: 2.450
100. Incurvaia,L., Fanale, D., Badalamenti, G., Brando, C., Bono, M., De Luca, I., Algeri, L., Bonasera, A., Corsini, L. R., Scurria, S., Iovanna, J. L., Russo, A., and Bazan, V. A "Lymphocyte MicroRNA Signature" as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming. *Cancers (Basel)*. 2020;12:E3396
I.F.: 6.126
101. Incurvaia,L., Fanale, D., Badalamenti, G., Porta, C., Olive, D., De Luca, I., Brando, C., Rizzo, M., Messina, C., Rediti, M., Russo, A., Bazan, V., and Iovanna, J. L. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. *Oncoimmunology*. 2020;9:e1832348
I.F.: 5.869
102. Innocenti,F., Mills, S. C., Sanoff, H., Ciccolini, J., Lenz, H. J., and Milano, G. All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide. *JCO Oncol Pract*. 2020;16:793-798.
I.F.: 0



103. Iovanna, J. L. Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer. *Transl Oncol.* 2020;14:100965
I.F.: 3.558
104. Isogawa, A., Fuchs, R. P., and Fujii, S. Chromatin Pull-Down Methodology Based on DNA Triple Helix Formation. *Methods Mol Biol.* 2020;2119:183-199.
I.F.: 0
105. Ivanov, V., Farnault, L., Mercier, C., Colavolpe, C., Venton, G., Colle, J., Lepidi, H., Arnoux, I., Nicolino-Brunet, C., Berda-Haddad, Y., Fanciullino, R., Ivanov, G., and Costello, R. Different sensitivity of CD19-positive bone marrow and lymph node lymphoblasts may cause resistance to blinatumomab in relapsed B-cell acute lymphoblastic leukemia/lymphoma. *Leuk Lymphoma.* 2020;61:1230-1233.
I.F.: 2.969
106. Iwase, T., Harano, K., Masuda, H., Kida, K., Hess, K. R., Wang, Y., Dirix, L., Van Laere, S. J., Lucci, A., Krishnamurthy, S., Woodward, W. A., Layman, R. M., Bertucci, F., and Ueno, N. T. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. *BMC Cancer.* 2020;20:430
I.F.: 3.150
107. Janssens, G. O., Mandeville, H. C., Timmermann, B., Maduro, J. H., Alapetite, C., Padovani, L., Horan, G., Lassen-Ramshad, Y., Dieckmann, K., Ruebe, C., Thorp, N., Gandola, L., Ajithkumar, T., and Boterberg, T. A rapid review of evidence and recommendations from the SIOPE Radiation Oncology working group to help mitigate for reduced paediatric radiotherapy capacity during the COVID-19 pandemic or other crises. *Radiother Oncol.* 2020;148:216-222.
I.F.: 4.856
108. Jaune-Pons, E. and Vasseur, S. Role of amino acids in regulation of ROS balance in cancer. *Arch Biochem Biophys.* 2020;689:108438
I.F.: 3.391
109. Juiz, N., Elkaoutari, A., Bigonnet, M., Gayet, O., Roques, J., Nicolle, R., Iovanna, J. L., and Dusetti, N. Basal-like and classical cells coexist in pancreatic cancer revealed by single-cell analysis on biopsy-derived pancreatic cancer organoids from the classical subtype. *FASEB J.* 2020;34:12214-12228.
I.F.: 4.966
110. Lan, W., Santofimia-Castano, P., Xia, Y., Zhou, Z., Huang, C., Fraunhofer, N., Barea, D., Cervello, M., Giannitrapani, L., Montalto, G., Peng, L., and Iovanna, J. L. Targeting NUPR1 with the small compound ZZW-115 is an efficient strategy to treat hepatocellular carcinoma. *Cancer Lett.* 2020;486:8-17.
I.F.: 7.360
111. Lan, W., Santofimia-Castano, P., Swayden, M., Xia, Y., Zhou, Z., Audebert, S., Camoin, L., Huang, C., Peng, L., Jimenez-Alesanco, A., Velazquez-Campoy, A., Abian, O., Lomberk, G., Urrutia, R., Rizzuti, B., Geli, V., Soubeyran, P., Neira, J. L., and Iovanna, J. L. ZZW-115-dependent inhibition of NUPR1 nuclear translocation sensitizes cancer cells to genotoxic agents. *JCI Insight.* 2020;5:e138117
I.F.: 6.205
112. Laurent, C., Nicolae, A., Laurent, C., Le Bras, F., Haioun, C., Fataccioli, V., Amara, N., Adelaide, J., Guille, A., Schiano, J. M., Tesson, B., Traverse-Glehen, A., Chenard, M. P., Mescam, L., Moreau, A., Chassagne-Clement, C., Somja, J., Escudie, F., Andre, M., Martin, N., Lacroix, L., Lemonnier, F., Hamy-Petit, A. S., Reyat, F., Bannier, M., Oberic, L., Prade, N., Frenois, F. X., Beldi-Ferchiou, A., Delfau-Larue, M. H., Bouabdallah, R., Birnbaum, D., Brousset, P., Xerri, L., and Gaulard, P. Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL. *Blood.* 2020;135:360-370.
I.F.: 17.794
113. Le Luedec, F., Leenhardt, F., Marin, C., Chatelut, E., Evrard, A., and Ciccolini, J. Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective. *Vaccines (Basel).* 2020;8:E632
I.F.: 4.086

114. Leblanc,R., Kashyap, R., Barral, K., Egea-Jimenez, A. L., Kovalskyy, D., Feracci, M., Garcia, M., Derviaux, C., Betzi, S., Ghossoub, R., Platonov, M., Roche, P., Morelli, X., Hoffer, L., and Zimmermann, P. Pharmacological inhibition of syntenin PDZ2 domain impairs breast cancer cell activities and exosome loading with syndecan and EpCAM cargo. *J Extracell Vesicles*. 2020;10:e12039
I.F.: 14.976
115. Li,T., Martin, E., Abada, Y. S., Boucher, C., Ces, A., Youssef, I., Fenaux, G., Forand, Y., Legrand, A., Nachiket, N., Dhenain, M., Hermine, O., Dubreuil, P., Delarasse, C., and Delatour, B. Effects of Chronic Masitinib Treatment in APPPS1dE9 Transgenic Mice Modeling Alzheimer's Disease. *J Alzheimers Dis*. 2020;76:1339-1345.
I.F.: 3.909
116. Madani,A., Mallick, I., Guy, A., Crauste, C., Durand, T., Fourquet, P., Audebert, S., Camoin, L., Canaan, S., and Cavalier, J. F. Dissecting the antibacterial activity of oxadiazolone-core derivatives against *Mycobacterium abscessus*. *PLoS One*. 2020;15:e0238178
I.F.: 2.740
117. Madelain,V., Duthey, A., Mentre, F., Jacquot, F., Solas, C., Lacarelle, B., Vallve, A., Barron, S., Barrot, L., Munweiler, S., Thomas, D., Carboneille, C., Raoul, H., de Lamballerie, X., and Guedj, J. Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates. *Antiviral Res*. 2020;177:104758
I.F.: 4.101
118. Maestroni,L., Reyes, C., Vaurs, M., Gachet, Y., Tournier, S., Geli, V., and Coulon, S. Nuclear envelope attachment of telomeres limits TERRA and telomeric rearrangements in quiescent fission yeast cells. *Nucleic Acids Res*. 2020;48:3029-3041.
I.F.: 11.502
119. Maestroni,L., Audry, J., Luciano, P., Coulon, S., Geli, V., and Corda, Y. RPA and Pif1 cooperate to remove G-rich structures at both leading and lagging strand. *Cell Stress*. 2020;4:48-63.
I.F.: 0
120. Maillard,M., Chevreau, C., Le Louedec, F., Cassou, M., Delmas, C., Gourdain, L., Blay, J. Y., Cupissol, D., Bompas, E., Italiano, A., Isambert, N., Delcambre-Lair, C., Penel, N., Bertucci, F., Guillemet, C., Pleneccassagnes, J., Foulon, S., Chatelut, E., Le Cesne, A., and Thomas, F. Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma. *Cancers (Basel)*. 2020;12:E3647
I.F.: 6.126
121. Malleter,M., Tauzin, S., Bessede, A., Castellano, R., Goubard, A., Godey, F., Leveque, J., Jezequel, P., Campion, L., Campone, M., Ducret, T., MacGrogan, G., Debure, L., Collette, Y., Vacher, P., and Legembre, P. Correction: CD95L Cell Surface Cleavage Triggers a Prometastatic Signaling Pathway in Triple-Negative Breast Cancer. *Cancer Res*. 2020;80:639
I.F.: 9.727
122. Manai,M., Doghri, R., Finetti, P., Mrad, K., Bouabsa, R., Manai, M., Birnbaum, D., Bertucci, F., Charfi, L., and Driss, M. Overexpression of Annexin A1 Is an Independent Predictor of Longer Overall Survival in Epithelial Ovarian Cancer. *In Vivo*. 2020;34:177-184.
I.F.: 1.541
123. Marie,L., Robert, M., Montana, L., De Dominicis, F., Ezzedine, W., Caiazzo, R., Fournel, L., Mancini, A., Kassir, R., Boullu, S., Barthet, M., D'Journo, X. B., and Bege, T. A French National Study on Gastropleural and Gastrobronchial Fistulas After Bariatric Surgery: the Impact of Therapeutic Strategy on Healing. *Obes Surg*. 2020;30:3111-3118.
I.F.: 3.412
124. Marin,C., Krache, A., Palmaro, C., Lucas, M., Hilaire, V., Ugdonne, R., De Victor, B., Quaranta, S., Solas, C., Lacarelle, B., and Ciccolini, J. A simple and rapid UPLC-UV method for determining DPD functional status in patients with cancer. *Clin Transl Sci*. 2020;13:761-768.
I.F.: 3.373

125. Masoud,R., Reyes-Castellanos, G., Lac, S., Garcia, J., Dou, S., Shintu, L., Abdel Hadi, N., Gicquel, T., El Kaoutari, A., Dieme, B., Tranchida, F., Cormareche, L., Borge, L., Gayet, O., Pasquier, E., Dusetti, N., Iovanna, J. L., and Carrier, A. Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer. *Cell Rep Med.* 2020;1:100143
I.F.: 0
126. Matmati,S., Lambert, S., Geli, V., and Coulon, S. Telomerase Repairs Collapsed Replication Forks at Telomeres. *Cell Rep.* 2020;30:3312-3322.e3.
I.F.: 8.109
127. Mazieres,J., Cropet, C., Montane, L., Barlesi, F., Souquet, P. J., Quantin, X., Dubos-Arvis, C., Otto, J., Favier, L., Avrillon, V., Cadranel, J., Moro-Sibilot, D., Monnet, I., Westeel, V., Le Treut, J., Brain, E., Tredaniel, J., Jaffro, M., Collot, S., Ferretti, G. R., Tiffon, C., Mahier-Ait, O. C., and Blay, J. Y. Vemurafenib in non-small-cell lung cancer patients with BRAF(V600) and BRAF(nonV600) mutations. *Ann Oncol.* 2020;31:289-294.
I.F.: 18.274
128. Mazieres,J., Barlesi, F., Rouquette, I., Molinier, O., Besse, B., Monnet, I., Audigier-Valette, C., Toffart, A. C., Renault, P. A., Fraboulet, S., Hiret, S., Mennecier, B., Debieuvre, D., Westeel, V., Masson, P., Madroszyk-Flandin, A., Pichon, E., Cortot, A. B., Amour, E., Morin, F., Zalcman, G., Moro-Sibilot, D., and Souquet, P. J. Randomized phase II trial evaluating treatment with EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial. *Clin Cancer Res.* 2020;26:3172-3181.
I.F.: 10.107
129. Mescam,L., Camus, V., Schiano, J. M., Adelaide, J., Picquenot, J. M., Guille, A., Bannier, M., Ruminy, P., Viailly, P. J., Jardin, F., Bouabdallah, R., Brenot-Rossi, I., Bohers, E., Robe, C., Laurent, C., Birnbaum, D., Wotherspoon, A., Gaulard, P., and Xerri, L. EBV+ diffuse large B-cell lymphoma associated with chronic inflammation expands the spectrum of breast implant-related lymphomas. *Blood.* 2020;135:2004-2009.
I.F.: 17.794
130. Mezni,E., Vicier, C., Guerin, M., Sabatier, R., Bertucci, F., and Goncalves, A. New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?pi. *Cancers (Basel).* 2020;12:1573
I.F.: 6.126
131. Milano,G., Innocenti, F., and Ciccolini, J. The association between adverse events and outcome under checkpoint inhibitors: Where is the deal? *Transl Oncol.* 2020;14:100952
I.F.: 3.558
132. Mogenet,A., Tomasini, P., Greillier, L., and Barlesi, F. Toxicités à prévoir avec les futures immunothérapies ou associations. *Bull Cancer.* 2020;107:1069-1078.
I.F.: 0.912
133. Montemagno,C., Hagege, A., Borchiellini, D., Thamphy, B., Rastoin, O., Ambrosetti, D., Iovanna, J. L., Rioux-Leclercq, N., Porta, C., Negrier, S., Ferrero, J. M., Chamorey, E., Pages, G., and Dufies, M. Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma. *Oncoimmunology.* 2020;9:e1846901
I.F.: 5.689
134. Mora,J.S., Genge, A., Chio, A., Estol, C. J., Chaverri, D., Hernandez, M., MarIn, S., Mascias, J., Rodriguez, G. E., Povedano, M., Paipa, A., Dominguez, R., Gamez, J., Salvado, M., Lunetta, C., Ballario, C., Riva, N., Mandrioli, J., Moussy, A., Kinet, J. P., Auclair, C., Dubreuil, P., Arnold, V., Mansfield, C. D., and Hermine, O. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. *Amyotroph Lateral Scler Frontotemporal Degener.* 2020;21:5-14.
I.F.: 3.286
135. Mosele,F., Stefanovska, B., Lusque, A., Tran Dien, A., Garberis, I., Droin, N., Le Tourneau, C., Sablin, M. P., Lacroix, L., Enrico, D., Miran, I., Jovelet, C., Bieche, I., Soria, J. C., Bertucci, F., Bonnefoi, H., Campone, M., Dalenc, F., Bachelot, T., Jacquet,



- A., Jimenez, M., and Andre, F. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. *Ann Oncol.* 2020;31:377-386.
I.F.: 18.274
136. Muller,S., Sindikubwabo, F., Caneque, T., Lafon, A., Versini, A., Lombard, B., Loew, D., Wu, T. D., Ginestier, C., Charafe-Jauffret, E., Durand, A., Vallot, C., Baulande, S., Servant, N., and Rodriguez, R. CD44 regulates epigenetic plasticity by mediating iron endocytosis. *Nat Chem.* 2020;12:929-938.
I.F.: 21.687
137. Naulaerts,S., Menden, M. P., and Ballester, P. J. Concise Polygenic Models for Cancer-Specific Identification of Drug-Sensitive Tumors from Their Multi-Omics Profiles. *Biomolecules.* 2020;10:E963
I.F.: 4.082
138. Neant,N. and Solas, C. Drug-Drug Interactions Potential of Direct Acting Antivirals for the treatment of Chronic Hepatitis C infection. *Int J Antimicrob Agents.* 2020;56:105571
I.F.: 4.621
139. Neant,N., Le, M. P., Bouazza, N., Gattacceca, F., Yazdanpanah, Y., Dhiver, C., Bregigeon, S., Mokhtari, S., Peytavin, G., Tamalet, C., Descamps, D., Lacarelle, B., and Solas, C. Usefulness of Therapeutic Drug Monitoring of Rilpivirine and relationship with virologic response and resistance in a cohort of naive and pre-treated HIV-infected patients. *Br J Clin Pharmacol.* 2020;86:2404-2413.
I.F.: 3.740
140. Neira,J.L., Rizzuti, B., Jimenez-Alesanco, A., Palomino-Schatzlein, M., Abian, O., Velazquez-Campoy, A., and Iovanna, J. L. A Phosphorylation-Induced Switch in the Nuclear Localization Sequence of the Intrinsically Disordered NUPR1 Hampers Binding to Importin. *Biomolecules.* 2020;10:E1313
I.F.: 4.082
141. Neira,J.L., Rizzuti, B., Jimenez-Alesanco, A., Abian, O., Velazquez-Campoy, A., and Iovanna, J. L. The Parologue of the Intrinsically Disordered Nuclear Protein 1 Has a Nuclear Localization Sequence that Binds to Human Importin alpha 3. *Int J Mol Sci.* 2020;21:E7428
I.F.: 4.556
142. Neron,M., Sajous, C., Thezenas, S., Piperno-Neumann, S., Reyat, F., Lae, M., Chakiba, C., Penel, N., Ryckewaert, T., Honore, C., Bertucci, F., Monneur, A., Salas, S., Duffaud, F., Saada-Bouزيد, E., Isambert, N., Brahmi, M., Ray-Coquard, I., Blay, J. Y., and Firmin, N. Impact of Metastasis Surgery and Alkylating-Agent-Based Chemotherapy on Outcomes of Metastatic Malignant Phyllodes Tumors: A Multicenter Retrospective Study. *Ann Surg Oncol.* 2020;27:1693-1699.
I.F.: 4.061
143. Neron,M., Sajous, C., Thezenas, S., Piperno-Neumann, S., Reyat, F., Lae, M., Chakiba, C., Michot, A., Penel, N., Honore, C., Owen, C., Bertucci, F., Salas, S., Saada-Bouزيد, E., Valentin, T., Bompas, E., Brahmi, M., Ray-Coquard, I., Blay, J. Y., and Firmin, N. Surgical Margins and Adjuvant Therapies in Malignant Phyllodes Tumors of the Breast: A Multicenter Retrospective Study. *Ann Surg Oncol.* 2020;27:1818-1827.
I.F.: 4.061
144. Nicolle,R., Blum, Y., Duconseil, P., Vanbrugghe, C., Brandone, N., Poizat, F., Roques, J., Bigonnet, M., Gayet, O., Rubis, M., Elarouci, N., Armenoult, L., Ayadi, M., De Reynies, A., Giovannini, M., Grandval, P., Garcia, S., Canivet, C., Cros, J., Bournet, B., Moutardier, V., Gilabert, M., Iovanna, J., Dusetti, N., and Buscail, L. Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer. *EBioMedicine.* 2020;57:102858
I.F.: 5.736
145. Nijmeijer,B.M., Eder, J., Langedijk, C. J. M., Kaptein, T. M., Meeussen, S., Zimmermann, P., Ribeiro, C. M. S., and Geijtenbeek, T. B. H. Syndecan 4 Upregulation on Activated Langerhans Cells Counteracts Langerin Restriction to Facilitate Hepatitis C Virus Transmission. *Front Immunol.* 2020;11:503
I.F.: 5.085

146. Olive,D., Chretien, A. S., Devillier, R., Rochigneux, P., Gorvel, L., and Nunes, J. Les glycosylations de PD-L1 sous les feux de la rampe. *Med Sci (Paris)*. 2020;36:552-555.
I.F.: 0.692
147. Olive,D. L'immunologie : les bases pour comprendre les traitements actuels et à venir. *Rev Malad Respir Actual*. 2020;12:2S31-2S35.
I.F.: 0
148. Olleik,H., Yacoub, T., Hoffer, L., Gnansounou, S. M., Benhaïem-Henry, K., Nicoletti, C., Mekhalfi, M., Pique, V., Perrier, J., Hijazi, A., Baydoun, E., Raymond, J., Piccerelle, P., Maresca, M., and Robin, M. Synthesis and Evaluation of the Antibacterial Activities of 13-Substituted Berberine Derivatives. *Antibiotics (Basel)*. 2020;9:E381
I.F.: 3.893
149. Opitz,I., Scherpereel, A., Berghmans, T., Psallidas, I., Glatzer, M., Rigau, D., Astoul, P., Bolukbas, S., Boyd, J., Coolen, J., De Bondt, C., De Ruysscher, D., Durieux, V., Faivre-Finn, C., Fennell, D. A., Galateau-Salle, F., Greillier, L., Hoda, M. A., Klepetko, W., Lacourt, A., McElnay, P., Maskell, N. A., Mutti, L., Pairon, J. C., Van Schil, P., van Meerbeeck, J. P., Waller, D., Weder, W., Putora, P. M., and Cardillo, G. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. *Eur J Cardiothorac Surg*. 2020;58:1-24.
I.F.: 3.486
150. Pelissier-Alicot,A.L., Kintz, P., Ameline, A., Bosdure, E., Chabrol, B., Neant, N., Torrents, R., Sastre, C., Baillif-Couniou, V., Tuchtan-Torrents, L., and Leonetti, G. Bromazepam intoxication in an infant: contribution of hair and nail analysis. *Drug Test Anal*. 2020;12:397-401.
I.F.: 2.903
151. Penel,N., Mir, O., Wallet, J., Ray-Coquard, I., Le Cesne, A., Italiano, A., Salas, S., Delcambre, C., Bompas, E., Bertucci, F., Saada-Bouزيد, E., Chaigneau, L., Chevreau, C., Brodowicz, T., Decoupigny, E., Vanseymortier, M., Laroche, L., Taieb, S., Le Deley, M. C., and Blay, J. Y. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic patients previously treated with both chemotherapy and pazopanib. *Eur J Cancer*. 2020;126:45-55.
I.F.: 7.275
152. Peperstraete,E., Lecerf, C., Collette, J., Vennin, C., Raby, L., Volkel, P., Angrand, P. O., Winter, M., Bertucci, F., Finetti, P., Lagadec, C., Meignan, S., Bourette, R. P., Bourhis, X. L., and Adriaenssens, E. Enhancement of Breast Cancer Cell Aggressiveness by lncRNA H19 and its Mir-675 Derivative: Insight into Shared and Different Actions. *Cancers (Basel)*. 2020;12:E1730
I.F.: 6.126
153. Platsaki,S., Zhou, X., Pinan-Lucarre, B., Delazun, V., Tu, H., Mansuelle, P., Fourquet, P., Bourne, Y., Bessereau, J. L., and Marchot, P. The Ig-like domain of Punctin/MADD-4 is the primary determinant for interaction with the ectodomain of neuroligin NLG-1. *Journal of Biological Chemistry*. 2020;295:16267-16279.
I.F.: 4.238
154. Pouzolles,M., Machado, A., Guilbaud, M., Irla, M., Gailhac, S., Barennes, P., Cesana, D., Calabria, A., Benedicenti, F., Serge, A., Raman, I., Li, Q. Z., Montini, E., Klatzmann, D., Adjali, O., Taylor, N., and Zimmermann, V. S. Intrathymic adeno-associated virus gene transfer rapidly restores thymic function and long-term persistence of gene-corrected T cells. *J Allergy Clin Immunol*. 2020;145:679-697.e5.
I.F.: 10.228
155. Qin,Z., Bi, L., Hou, X. M., Zhang, S., Zhang, X., Lu, Y., Li, M., Modesti, M., Xi, X. G., and Sun, B. Human RPA activates BLM's bidirectional DNA unwinding from a nick. *Elife*. 2020;9:e54098
I.F.: 7.080
156. Quoix,E., Audigier-Valette, C., Lavole, A., Molinier, O., Westeel, V., Barlesi, F., Le Treut, J., Pichon, E., Dauba, J., Otto, J., Moreau, L., Madelaine, J., Dumont, P., Margery, J., Debieuvre, D., Renault, P. A., Pujol, J. L., Langlais, A., Morin, F., Moro-

- Sibilot, D., and Souquet, P. J. Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial. *Eur J Cancer*. 2020;138:193-201.
I.F.: 7.275
157. Raynaud,A., Desrumeaux, K., Vidard, L., Termine, E., Baty, D., Chames, P., Vigne, E., and Kerfelec, B. Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response. *Oncoimmunology*. 2020;10:1854529
I.F.: 5.869
158. Remon,J., Passiglia, F., Ahn, M. J., Barlesi, F., Forde, P. M., Garon, E. B., Gettinger, S., Goldberg, S. B., Herbst, R. S., Horn, L., Kubota, K., Lu, S., Mezquita, L., Paz-Ares, L., Papat, S., Schalper, K. A., Skoulidis, F., Reck, M., Adjei, A. A., and Scagliotti, G. V. Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations. *J Thorac Oncol*. 2020;15:914-947.
I.F.: 13.357
159. Reyes-Castellanos,G., Masoud, R., and Carrier, A. Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies. *Biomedicines*. 2020;8:E270
I.F.: 4.717
160. Richard,F., Majjaj, S., Venet, D., Rothe, F., Pingitore, J., Boeckx, B., Marchio, C., Clatot, F., Bertucci, F., Mariani, O., Galant, C., Van den Eynden, G. G., Salgado, R., Biganzoli, E., Lambrechts, D., Vincent-Salomon, A., Pruneri, G., Larsimont, D. P., Sotiriou, C., and Desmedt, C. Characterization of stromal tumor-infiltrating lymphocytes and genomic alterations in metastatic lobular breast cancer. *Clin Cancer Res*. 2020;26:6254-6565.
I.F.: 10.107
161. Robson,F., Khan, K. S., Le, T. K., Paris, C., Demirbag, S., Barfuss, P., Rocchi, P., and Ng, W. L. Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting. *Mol Cell*. 2020;80:1136-1138.
I.F.: 15.584
162. Robson,F., Khan, K. S., Le, T. K., Paris, C., Demirbag, S., Barfuss, P., Rocchi, P., and Ng, W. L. Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting. *Mol Cell*. 2020;79:710-727.
I.F.: 15.584
163. Rochigneux,P., Garcia, A. J., Chanez, B., Madroszyk, A., Olive, D., and Garon, E. B. Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? ASystematic Review. *Front Immunol*. 2020;11:1036
I.F.: 5.085
164. Rodallec,A., Franco, C., Robert, S., Sicard, G., Giacometti, S., Lacarelle, B., Bouquet, F., Savina, A., Lacroix, R., Dignat-George, F., Ciccolini, J., Poncelet, P., and Fanciullino, R. Prototyping Trastuzumab Docetaxel Immunoliposomes with a New FCM-Based Method to Quantify Optimal Antibody Density on Nanoparticles. *Sci Rep*. 2020;10:4147
I.F.: 3.998
165. Rodallec,A., Sicard, G., Giacometti, S., Carre, M., Maia, T., Valette, M., Bouquet, F., Savina, A., Lacarelle, B., Ciccolini, J., and Fanciullino, R. Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3). *Anticancer Drugs*. 2020;31:463-472.
I.F.: 2.260
166. Rodriguez-Ruiz,L., Lozano-Gil, J. M., Lachaud, C., Mesa-Del-Castillo, P., Cayuela, M. L., Garcia-Moreno, D., Perez-Oliva, A. B., and Mulero, V. Zebrafish Models to Study Inflammasome-Mediated Regulation of Hematopoiesis. *Trends Immunol*. 2020;41:1116-1127.
I.F.: 13.422
167. Roelands,J., Hendrickx, W., Zoppoli, G., Mall, R., Saad, M., Halliwill, K., Curigliano, G., Rinchai, D., Decock, J., Delogu, L. G., Turan, T., Samayoa, J., Chouchane, L., Ballestrero, A., Wang, E., Finetti, P., Bertucci, F., Miller, L. D., Galon, J., Marincola, F.

- M., Kuppen, P. J. K., Ceccarelli, M., and Bedognetti, D. Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response. *J Immunother Cancer*. 2020;8:e000617
I.F.: 9.913
168. Roger,E., Martel, S., Bertrand-Chapel, A., Depollier, A., Chuvin, N., Pommier, R. M., Yacoub, K., Caligaris, C., Cardot-Ruffino, V., Chauvet, V., Aires, S., Mohkam, K., Mabrut, J. Y., Adham, M., Fenouil, T., Hervieu, V., Broutier, L., Castets, M., Neuzillet, C., Cassier, P. A., Tomasini, R., Sentis, S., and Bartholin, L. Correction: Schwann cells support oncogenic potential of pancreatic cancer cells through TGFbeta signaling. *Cell Death Dis*. 2020;11:57
I.F.: 6.304
169. Roux,C., Revon-Riviere, G., Gentet, J. C., Verschuur, A., Scavarda, D., Saultier, P., Appay, R., Padovani, L., and Andre, N. Metronomic Maintenance With Weekly Vinblastine After Induction With Bevacizumab-Irinotecan in Children With Low-grade Glioma Prevents Early Relapse. *J Pediatr Hematol Oncol*. 2020
I.F.: 1.016
170. Rypens,C., Marsan, M., Van Berckelaer, C., Billiet, C., Melis, K., Lopez, S. P., Van Dam, P., Devi, G. R., Finetti, P., Ueno, N. T., Bertucci, F., Dirix, P., Neven, P., Vermeulen, P., Dirix, L., and Van Laere, S. J. Inflammatory breast cancer cells are characterized by abrogated TGFbeta1-dependent cell motility and SMAD3 activity. *Breast Cancer Res Treat*. 2020;180:385-395.
I.F.: 3.831
171. Salaun,P.Y., Abgral, R., Malard, O., Querellou-Lefranc, S., Quere, G., Wartski, M., Coriat, R., Hindie, E., Taieb, D., Tabarin, A., Girard, A., Grellier, J. F., Brenot-Rossi, I., Groheux, D., Rousseau, C., Deandreis, D., Alberini, J. L., Bodet-Milin, C., Itti, E., Casasnovas, O., Kraeber-Bodere, F., Moreau, P., Philip, A., Balleyguier, C., Luciani, A., and Cachin, F. Good clinical practice recommendations for the use of PET/CT in oncology. *Eur J Nucl Med Mol Imaging*. 2020;47:28-50.
I.F.: 7.081
172. Santofimia-Castano,P., Rizzuti, B., Xia, Y., Abian, O., Peng, L., Velazquez-Campoy, A., Neira, J. L., and Iovanna, J. L. Targeting intrinsically disordered proteins involved in cancer. *Cell Mol Life Sci*. 2020;77:1695-1707.
I.F.: 6.496
173. Santoni,M.J., Kashyap, R., Camoin, L., and Borg, J. P. The Scribble family in cancer: twentieth anniversary. *Oncogene*. 2020;39:7019-7033.
I.F.: 7.971
174. Sazanova,E.S., Gracheva, I. A., Allegro, D., Barbier, P., Combes, S., Svirshchetskaya, E. V., and Fedorov, A. Y. Alcolchicinoids bearing a Michael acceptor fragment for possible irreversible binding of tubulin. *RSC Med Chem*. 2020;11:696-706.
I.F.: 0
175. Scherpereel,A., Opitz, I., Berghmans, T., Psallidas, I., Glatzer, M., Rigau, D., Astoul, P., Bolukbas, S., Boyd, J., Coolen, J., De, B. C., De Ruysscher, D., Durieux, V., Faivre-Finn, C., Fennell, D., Galateau-Salle, F., Greillier, L., Hoda, M. A., Klepetko, W., Lacourt, A., McElnay, P., Maskell, N. A., Mutti, L., Pairon, J. C., Van Schil, P., van Meerbeeck, J. P., Waller, D., Weder, W., Cardillo, G., and Putora, P. M. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. *Eur Respir J*. 2020;55:1900953
I.F.: 12.339
176. Schottlaender,L.V., Abeti, R., Jaunmuktane, Z., Macmillan, C., Chelban, V., O'Callaghan, B., McKinley, J., Maroofian, R., Efthymiou, S., Athanasiou-Fragkouli, A., Forbes, R., Soutar, M. P. M., Livingston, J. H., Kalmar, B., Swayne, O., Hotton, G., Pittman, A., Mendes de Oliveira, J. R., De Grandis, M., Richard-Loendt, A., Launchbury, F., Althonayan, J., McDonnell, G., Carr, A., Khan, S., Beetz, C., Bisgin, A., Tug Bozdogan, S., Begtrup, A., Torti, E., Greensmith, L., Giunti, P., Morrison, P. J., Brandner, S., Aurrand-Lions, M., and Houlden, H. Bi-allelic JAM2 Variants Lead to Early-Onset Recessive Primary Familial Brain Calcification. *Am J Hum Genet*. 2020;106:412-421.
I.F.: 10.502

177. Schwartzberg,L.S., Horinouchi, H., Chan, D., Chernilo, S., Tsai, M. L., Isla, D., Escriu, C., Bennett, J. P., Clark-Langone, K., Svedman, C., and Tomasini, P. Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance. *NPJ Precis Oncol.* 2020;4:15
I.F.: 7.717
178. Shchegravina,E.S., Svirshchevskaya, E. V., Combes, S., Allegro, D., Barbier, P., Gigant, B., Varela, P. F., Gavryushin, A. E., Kobanova, D. A., Shchekotikhin, A. E., and Fedorov, A. Y. Discovery of dihydrofuranoalcolchicinoids - Highly potent antimetabolic agents with low acute toxicity. *Eur J Med Chem.* 2020;207:112724
I.F.: 5.572
179. Shigeta,K., Matsui, A., Kikuchi, H., Klein, S., Mamessier, E., Chen, I. X., Aoki, S., Kitahara, S., Inoue, K., Shigeta, A., Hato, T., Ramjiawan, R. R., Staiculescu, D., Zopf, D., Fiebig, L., Hobbs, G. S., Quaas, A., Dima, S., Popescu, I., Huang, P., Munn, L. L., Cobbold, M., Goyal, L., Zhu, A. X., Jain, R. K., and Duda, D. G. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. *J Immunother Cancer.* 2020;8:e001435
I.F.: 10.252
180. Sicard,G., Paris, C., Giacometti, S., Rodallec, A., Ciccolini, J., Rocchi, P., and Fanciullino, R. Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Grafted with Trastuzumab: A Proof-of-Concept Study in Prostate Cancer. *Pharmaceutics.* 2020;12:E1166
I.F.: 4.221
181. Sicard,G., Fina, F., Fanciullino, R., Barlesi, F., and Ciccolini, J. Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy. *Pharmaceutics.* 2020;12:E758
I.F.: 4.421
182. Siret,C., Collignon, A., Silvy, F., Robert, S., Cheyrol, T., Andre, P., Rigot, V., Iovanna, J. L., van de Pavert, S., Lombardo, D., Mas, E., and Martirosyan, A. Deciphering the Crosstalk Between Myeloid-Derived Suppressor Cells and Regulatory T Cells in Pancreatic Ductal Adenocarcinoma. *Front Immunol.* 2020;10:3070
I.F.: 5.085
183. Takedachi,A., Despras, E., Scaglione, S., Guerois, R., Guervilly, J. H., Blin, M., Audebert, S., Camoin, L., Hasanova, Z., Schertzer, M., Guille, A., Churikov, D., Callebaut, I., Naim, V., Chaffanet, M., Borg, J. P., Bertucci, F., Revy, P., Birnbaum, D., Londono-Vallejo, A., Kannouche, P. L., and Gaillard, P. H. L. SLX4 interacts with RTEL1 to prevent transcription-mediated DNA replication perturbations. *Nat Struct Mol Biol.* 2020;27:438-449.
I.F.: 11.980
184. Tallet,A., Racadot, S., Boher, J. M., Cohen, M., Barrou, J., Houvenaeghel, G., Gutowski, M., Delmond, L., and Lemanski, C. The actual benefit of intraoperative radiation therapy using 50 kV x-rays in early breast cancer: A retrospective study of 676 patients. *Breast J.* 2020;26:2145-2150.
I.F.: 1.991
185. Thomas,P.A., Couderc, A. L., Boulate, D., Greillier, L., Charvet, A., Brioude, G., Trousse, D., D'Journo, X. B., Barlesi, F., and Loundou, A. Early-stage non-small cell lung cancer beyond life expectancy: Still not too old for surgery? *Lung Cancer.* 2020;152:86-93.
I.F.: 4.702
186. Thuault,S., Mamelonet, C., Salameh, J., Ostacolo, K., Chanez, B., Salaun, D., Baudalet, E., Audebert, S., Camoin, L., and Badache, A. A proximity-labeling proteomic approach to investigate invadopodia molecular landscape in breast cancer cells. *Sci Rep.* 2020;10:6787
I.F.: 3.998
187. Tomasini,P., Barlesi, F., Gilles, S., Nanni-Metellus, I., Soffietti, R., Denicolai, E., Pellegrino, E., Bialecki, E., Ouafik, L., and Metellus, P. Comparative genomic analysis of primary tumors and paired brain metastases in lung cancer patients by whole exome sequencing: a pilot study. *Oncotarget.* 2020;11:4648-4654.
I.F.: 0

188. Toulmonde, M., Lucchesi, C., Verbeke, S., Crombe, A., Adam, J., Geneste, D., Chaire, V., Laroche-Clary, A., Perret, R., Bertucci, F., Bertolo, F., Bianchini, L., Dadone-Montaudie, B., Hembrough, T., Sweet, S., Kim, Y. J., Cecchi, F., Le Loarer, F., and Italiano, A. High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies. *EBioMedicine*. 2020;62:103131
I.F.: 5.736
189. Touret, F., Gilles, M., Barral, K., Nougairede, A., van Helden, J., Decroly, E., de Lamballerie, X., and Coutard, B. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. *Sci Rep*. 2020;10:13093
I.F.: 3.998
190. Trama, A., Proto, C., Whisenant, J. G., Torri, V., Cortellini, A., Michielin, O., Barlesi, F., Dingemans, A. C., Van Meerbeeck, J., Pancaldi, V., Mazieres, J., Soo, R. A., Leigh, N. B., Peters, S., Wakelee, H., Horn, L., Hellmann, M., Wong, S. K., Garassino, M. C., and Baena, J. Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERA-VOLT Experience. *Cancer Cell*. 2020;38:602-604.
I.F.: 26.602
191. Travert, C., Tomasini, P., and Barlesi, F. Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer? *Transl Lung Cancer Res*. 2020;9:401-405.
I.F.: 5.132
192. Travert, C., Barlesi, F., Greillier, L., and Tomasini, P. Immune Oncology Biomarkers in Lung Cancer: an Overview. *Curr Oncol Rep*. 2020;22:107
I.F.: 3.828
193. Urrutia, G., Salmonson, A., Toro-Zapata, J. A., de Assuncao, T. M., Mathison, A., Dusetti, N., Iovanna, J. L., Urrutia, R., and Lomber, G. Combined Targeting of G9a and Checkpoint kinase 1 Synergistically Inhibits Pancreatic Cancer Cell Growth by Replication Fork Collapse. *Mol Cancer Res*. 2020;18:448-462.
I.F.: 4.630
194. Vaghi, C., Rodallec, A., Fanciullino, R., Ciccolini, J., Mochel, J. P., Mastri, M., Poignard, C., Ebos, J. M. L., and Benzekry, S. Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors. *PLoS Comput Biol*. 2020;16:e1007178
I.F.: 4.700
195. van de Haar, J., Hoes, L. R., Coles, C. E., Seamon, K., Frohling, S., Jager, D., Valenza, F., de Braud, F., De Petris, L., Bergh, J., Ernberg, I., Besse, B., Barlesi, F., Garralda, E., Piris-Gimenez, A., Baumann, M., Apolone, G., Soria, J. C., Tabernero, J., Caldas, C., and Voest, E. E. Author Correction: Caring for patients with cancer in the COVID-19 era. *Nat Med*. 2020;26:1146
I.F.: 36.130
196. van de Haar, J., Hoes, L. R., Coles, C. E., Seamon, K., Frohling, S., Jager, D., Valenza, F., de Braud, F., De Petris, L., Bergh, J., Ernberg, I., Besse, B., Barlesi, F., Garralda, E., Piris-Gimenez, A., Baumann, M., Apolone, G., Soria, J. C., Tabernero, J., Caldas, C., and Voest, E. E. Caring for patients with cancer in the COVID-19 era. *Nat Med*. 2020;26:665-671.
I.F.: 36.130
197. Vila-Navarro, E., Fernandez-Castaner, E., Rovira-Rigau, M., Raimondi, G., Vila-Casadesus, M., Lozano, J. J., Soubeyran, P., Iovanna, J. L., Castells, A., Fillat, C., and Gironella, M. MiR-93 is related to poor prognosis in pancreatic cancer and promotes tumor progression by targeting microtubule dynamics. *Oncogenesis*. 2020;9:43
I.F.: 6.119
198. Vitte, J., Diallo, A. B., Boumaza, A., Lopez, A., Michel, M., Allardet-Servent, J., Mezouar, S., Sereme, Y., Busnel, J. M., Miloud, T., Malergue, F., Morange, P. E., Halfon, P., Olive, D., Leone, M., and Mege, J. L. A granulocytic signature identifies COVID-19 and its severity. *J Infect Dis*. 2020;222:1985-1996.
I.F.: 5.022
199. Voisset, E., Brenet, F., Lopez, S., and De Sepulveda, P. SRC-Family Kinases in Acute Myeloid Leukaemia and Mastocytosis. *Cancers (Basel)*. 2020;12:E1996 I.F.: 6.126
200. Vyborova, A., Beringer, D. X., Fasci, D., Karaiskaki, F., van Diest, E., Kramer, L., de Haas, A., Sanders, J., Janssen, A., Straetmans, T., Olive, D., Leusen, J. H., Boutin, L., Nedellec, S., Schwartz, S. L., Wester, M. J., Lidke, K. A., Scotet, E., Lidke, D., Heck, A. J., Sebestyen, Z., and Kuball, J. $\text{I}^{\text{3}}\text{9}\hat{\text{I}}\text{2T}$



cell diversity and the receptor interface with tumor cells. *J Clin Invest.* 2020;130:4637-4651.
I.F.: 11.864

201. Whisenant, J.G., Trama, A., Torri, V., De Toma, A., Viscardi, G., Cortellini, A., Micheilin, O., Barlesi, F., Dingemans, A. C., Van Meerbeeck, J., Rancaldi, V., Seo, R. A., Leigh, N. B., Peters, S., Wakelee, H., Garassino, M. C., and Horn, L. TERA-VOLT: Therapeutic Cancers International COVID-19 Collaboration. *Cancer Cell.* 2020;37:742-745.
I.F.: 26.602

202. Wirth, L.J., Sherman, E., Robinson, B., Solomon, B., Kang, H., Lorch, J., Worden, F., Brose, M., Patel, J., Leboulleux, S., Godbert, Y., Barlesi, F., Morris, J. C., Owonikoko, T. K., Tan, D. S. W., Gautschi, O., Weiss, J., de La Fouchardiere, C., Burkard, M. E., Laskin, J., Taylor, M. H., Kroiss, M., Medioni, J., Goldman, J. W., Bauer, T. M., Levy, B., Zhu, V. W., Lakhani, N., Moreno, V., Ebata, K., Nguyen, M., Heirich, D., Zhu, E. Y., Huang, X., Yang, L., Kherani, J., Rothenberg, S. M., Drilon, A., Subbiah, V., Shah, M. H., and Cabanillas, M. E. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. *N Engl J Med.* 2020;383:825-835. I.F.: 74.699

203. Zaghdoudi, S., Decaup, E., Belhabib, I., Samain, R., Cassant-Sourdy, S., Rochotte, J., Brunel, A., Schlaepfer, D., Cros, J., Neuzillet, C., Strehaiano, M., Alard, A., Tomasini, R., Rajeeve, V., Perraud, A., Mathonnet, M., Pearce, O. M., Martineau, Y., Pyronnet, S., Bousquet, C., and Jean, C. FAK activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer. *EMBO Mol Med.* 2020;e12010
I.F.: 8.821

204. Zawati, I., Adouni, O., Finetti, P., Manai, M., Manai, M., Gamoudi, A., Birnbaum, D., Bertucci, F., and Mezlini, A. Adolescents and young adults with classical Hodgkin lymphoma in North Tunisia: Insights from an adult single-institutional study. *Cancer Radiother.* 2020;24:206-214.
I.F.: 1.014

205. Zhang, Y., Liu, X., Lin, Y., Lian, B., Lan, W., Iovanna, J. L., Liu, X., Peng, L., and Xia, Y. Novel triazole nucleoside analogues promote anticancer activity via both apoptosis and autophagy. *Chem Commun (Camb).* 2020;56:10014-10017.
I.F.: 5.996

206. Zhao, Y., Wu, Z., Chanal, M., Guillaumond, F., Goehrig, D., Bachy, S., Principe, M., Ziverec, A., Flaman, J. M., Collin, G., Tomasini, R., Pasternack, A., Ritvos, O., Vasseur, S., Bernard, D., Hennino, A., and Bertolino, P. Oncogene-induced senescence limits the progression of pancreatic neoplasia through production of Activin A. *Cancer Res.* 2020;80:3359-3371.
I.F.: 8.378